# CUMULATIVE INDEX 1995

## Volume 25

<table>
<thead>
<tr>
<th>Month</th>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>January</td>
<td>SURGICAL ONCOLOGY</td>
<td>1–255</td>
</tr>
<tr>
<td>March</td>
<td>LIVER DISEASE</td>
<td>257–525</td>
</tr>
<tr>
<td>May</td>
<td>DIABETES MELLITUS</td>
<td>527–766</td>
</tr>
<tr>
<td>July</td>
<td>FELINE DERMATOLOGY</td>
<td>767–1013</td>
</tr>
<tr>
<td>September</td>
<td>MANAGEMENT OF ORTHOPEDIC EMERGENCIES</td>
<td>1015–1230</td>
</tr>
<tr>
<td>November</td>
<td>TRANSFUSION MEDICINE</td>
<td>1231–1490</td>
</tr>
</tbody>
</table>

**Note:** Page numbers of article titles are in **boldface** type.

<table>
<thead>
<tr>
<th>Topic</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdomen, examination of, in trauma</td>
<td>1017</td>
</tr>
<tr>
<td>lymph nodes of, 153–154</td>
<td></td>
</tr>
<tr>
<td>lymphocenters of, 158</td>
<td></td>
</tr>
<tr>
<td>Abdominal mass, diagnostic imaging of,</td>
<td>193–200</td>
</tr>
<tr>
<td>algorithm for, 194</td>
<td></td>
</tr>
<tr>
<td>Abdominal surgery, in oncology patient,</td>
<td></td>
</tr>
<tr>
<td>infection with, 82–83</td>
<td></td>
</tr>
<tr>
<td>Abdominal vasculature, ultrasound anatomy of, 321</td>
<td></td>
</tr>
<tr>
<td>Abdominal wall defects, repair of, in surgical oncology, 104</td>
<td></td>
</tr>
<tr>
<td>Abscesses, in cats, 887–888</td>
<td></td>
</tr>
<tr>
<td>Acellular fluids, oxygen-carrying, for blood substitution, 1417–1439</td>
<td></td>
</tr>
<tr>
<td>possible applications for, 1420</td>
<td></td>
</tr>
<tr>
<td>Acetate tape preparations, in feline dermatology, 782–783</td>
<td></td>
</tr>
<tr>
<td>Acid-base balances, restoration of, in diabetic ketoacidosis, 642–644</td>
<td></td>
</tr>
<tr>
<td>Acid-base imbalance, and hepatic encephalopathy, 345</td>
<td></td>
</tr>
<tr>
<td>Acid-citrate-dextrose, in small animal transfusions, 1271</td>
<td></td>
</tr>
<tr>
<td>Acidosis, with canine blood transfusion, 1356</td>
<td></td>
</tr>
<tr>
<td>with diabetic ketoacidosis, 619–620</td>
<td></td>
</tr>
<tr>
<td>Acne, of face, in cats, 924–926</td>
<td></td>
</tr>
<tr>
<td>Acromegaly, and canine insulin resistance, management of, 706</td>
<td></td>
</tr>
<tr>
<td>and feline insulin resistance, management of, 705, 708</td>
<td></td>
</tr>
<tr>
<td>in cats, cutaneous manifestations of, 953–954</td>
<td></td>
</tr>
<tr>
<td>in diabetes mellitus, surgery in, 656–657</td>
<td></td>
</tr>
<tr>
<td>insulin resistance vs, 697–699</td>
<td></td>
</tr>
<tr>
<td>Actinic dermatitis, in cats, differential diagnosis of, 878</td>
<td></td>
</tr>
<tr>
<td>Actinic keratosis, in cats, 828–830, 962</td>
<td></td>
</tr>
<tr>
<td>of face, 926–927</td>
<td></td>
</tr>
<tr>
<td>of pinnae, 934–935</td>
<td></td>
</tr>
<tr>
<td>Actinomycotic infections, cutaneous, in cats, 888–890</td>
<td></td>
</tr>
<tr>
<td>Acute hypersensitivity transfusion reaction, canine, 1344–1346</td>
<td></td>
</tr>
<tr>
<td>clinical signs of, 1345</td>
<td></td>
</tr>
<tr>
<td>definition and pathophysiology of, 1344–1345</td>
<td></td>
</tr>
<tr>
<td>prevention of, 1346</td>
<td></td>
</tr>
<tr>
<td>treatment of, 1345–1346</td>
<td></td>
</tr>
<tr>
<td>Adenocarcinoma, ceruminous gland, in cats, 964–965</td>
<td></td>
</tr>
<tr>
<td>Adjuvant chemotherapy, 133–134</td>
<td></td>
</tr>
<tr>
<td>Adjuvant therapy, for chronic pain, in surgical oncology patient, 91–92</td>
<td></td>
</tr>
<tr>
<td>Adrenal, diagnostic imaging of, 198–200</td>
<td></td>
</tr>
<tr>
<td>Air embolism, as autotransfusion complication, 1302</td>
<td></td>
</tr>
<tr>
<td>with canine blood transfusion, 1355</td>
<td></td>
</tr>
<tr>
<td>Airway, examination of, in trauma, 1016</td>
<td></td>
</tr>
<tr>
<td>Airway/oxygenation, in resuscitation from hemorrhage, critical need for red blood cells in, 1369</td>
<td></td>
</tr>
<tr>
<td>Albumin, copper-binding by, 401</td>
<td></td>
</tr>
<tr>
<td>critical need for, 1385</td>
<td></td>
</tr>
<tr>
<td>deficit of, plasma needed to replace, calculation of, 1283</td>
<td></td>
</tr>
<tr>
<td>Aldosterone, for biliary cirrhosis, 382</td>
<td></td>
</tr>
</tbody>
</table>

1457
Alkaline phosphatase, serum, in cholestasis, 259-260
Alkylating agents, effects on wound healing, 115
Allergies, serologic tests for, in feline dermatology, 794-795
Alopecia, in cats, 851-870
diagnostic procedures in, 780
excessive shedding of whole hairs, 861-867
bacterial folliculitis, 866
demodicosis, 866-867
diabetes mellitus, 863
hyperadrenocorticism, 862
hypothyroidism, 862
nutritional disorders, 866
telogen effluvium, 864-865
in mosquito-bite hypersensitivity, 839
psychogenic, and excess hair loss, 858-861
Siamese, pinnal, 936
with atopy, 819
with pyoderma, 821
Alopecia areata, in cats, 863
Alopecia universalis, in cats, 852
Alpha-2 agonists, for trauma patient, 1078
Ambulation, aids to, in spinal fracture/luxation, 1170
Amino acids, consumption of, in liver disease, 496
metabolism of, and hepatic encephalopathy, 340-341
Aminotransferases, in liver disease, 258
Amitraz, for feline dermatoses, 988
Ammonia. See also Hyperammonemia.
generation of, in liver disease, 488
role in hepatic encephalopathy, 339-340
serum, tests of, 263-264
Ampicillin, for hepatic encephalopathy, 347
Amputation, in open fracture management, 1107-1108
Amylin, and obesity, 541
basal levels of, in normal vs diabetic cats, 540
concentrations of, in diabetes mellitus, 538-541
cosecretion with insulin, 536
effect on glycojen metabolism, 539
in pathogenesis of feline diabetes mellitus, 533-542
metabolic actions of, 537-538, 541-542
receptor antagonists to, for feline diabetes mellitus, 543
Amyloid, deposition of, in pathogenesis of feline diabetes mellitus, 533-542, 601
prerequisites for, 537
Analgesics, for pain, in surgical oncology patient, 87, 90-91
for trauma patient, 1084
postoperative, guidelines for, 1083
Anemia(s), blood components for, 1280-1282
erythropoietin for, 1443
with cancer, blood components for, 1403-1408
with liver cancer, 428
with liver disease, 266
Anesthesia, for surgery, in diabetes mellitus, 652
in trauma patient, 1073-1092
effect on brain, 1084-1085
effect on cardiovascular function, 1085
effect on respiratory function, 1087-1089
head injury, 1086
hemorrhage and, 1088
induction of, 1079-1081
barbiturates, 1079-1080
crash-type, 1079-1080
etomidate, 1080
ketamine with benzodiazepine, 1080
medium-fast, 1080-1081
propofol, 1080
slow mask, 1081
tiletamine-zolazepam, 1080
liver function and, 1088-1089
management of, check list prior to, 1073-1076
clinical examination and evaluation, 1073
complications associated with trauma, 1074-1076
preoperative stabilization, 1076
renal function and, 1089-1090
spleen and, 1088
with cardiac dysfunction, 1087
Anger, client counseling about, in euthanasia, 1054
Animal abuse, and orthopedic emergencies, 1055-1058
Anorexia, in cancer, 62-64
in liver disease, management of, 494
Antebrachiocarpal joint, penetrating injury to, radiographic view of, 1203
Antebrachium, osteosarcoma of, bone scintigram of, 191
Antibiotics, antitumor, effects on wound healing, 114-115
for feline dermatoses, 981-986
for hepatic encephalopathy, 345-347
in acute liver failure, 453
for infection, in surgical oncology patient, 78
for suppurative cholangitis/cholangiohepatitis, 377
in open fracture management, 1098-1099
in trauma management, 1023-1024
Anticancer therapy, for chronic pain, in surgical oncology patient, 90
Anticholinergic drugs, for trauma patient, 1077
Anticoagulant-preservatives, evaluation of, 1266–1268
for canine and feline blood storage, 1263–1276
in small animal transfusions, 1268–1273
formulation of, 1270
future of, 1273
Antifungals, for feline dermatoses, 986–987
topical, for feline dermatopytosis, 913
Antihistamines, for feline dermatoses, 989–990
Anti-inflammatories, for copper-associated hepatopathies, 410
Antileprosy drugs, for feline dermatoses, 987
Antiparasite drugs, for feline dermatoses, 988
Antithrombin II, in critical patients, interaction with thrombin, role of heparin in, 1381
Antitumor antibiotics, effects on wound healing, 114–115
Antivirals, for feline dermatoses, 989
Anti-vitamin K intoxication, transfusion for, 1397
Arginine, dietary, in hepatic encephalopathy, 349
Arteriovenous malformation, hepatic, appearance of, 333
Arthrodesis, for penetrating joint injuries, 1212–1213
Ascites, in biliary cirrhosis, 382
in portal hypertension, 466–468
treatment of, 476–480
medical, 476–478
surgical, 478–480
with generalized hepatomegaly, 308
Ascorbic acid, for copper-associated hepatopathies, 406
Aspiration biopsy, fine-needle, nonaspiration biopsy vs, 36–37
Asthenia, cutaneous, in cats, differential diagnosis of, 879
Atopy, in cats, and dermatoses, 818–820
and excess hair loss, 866
Aural hematoma, in cats, 935
Autoimmune chronic active hepatitis, 392–393
Autoimmune dermatoses, in cats, 825–828
Autologous transfusion. See Autotransfusion.
Autotransfusion, advantages of, 1293–1294
clot formation in, 1301
in emergency patient, 1291–1304
anticoagulation in, 1296
complications of, 1296–1302
air emboli, 1302
coagulopathy, 1297–1298
dissemination of malignancy, 1299–1300
hemolysis, 1297
microemboli, 1300
platelet disorders, 1298–1299
sepsis, 1299
filtration in, 1296
history of, 1291–1293
in small dog, 1295
methods of, 1294–1296
centrifuge-based cell salvage, 1294
direct aspiration and reinfusion, 1295
passive cannister collection system, 1294–1295
suction in, 1296
Axial pattern flaps, in surgical oncology, 104
Axonal degeneration, with long-term diabetes mellitus, 725
Azathioprine, for feline dermatoses, 995
for long-term hepatitis, 395
Azole antifungals, for feline dermatoses, 986–987
Bacteria, characteristics of, in surgical oncology patient, 77
contamination with, in canine blood transfusion, 1352–1353
Bacterial culture(s), in open fracture management, 1098–1099
Bacterial culture/susceptibility testing, in feline dermatology, 788–789
Bacterial diseases, in cats, cutaneous manifestations of, 948–949
Bacterial folliculitis, in cats, 820–821 and excessive shedding of whole hairs, 866
Bacterial infections, and acute liver failure, 440
Bacterial L-forms, cutaneous, in cats, 893
Bacterial translocation, in cancer catabolism, 64–65
Bacterial wound infection, with gunshot injuries, 1117
Baker biopsy punch, 287
Ballistics, and gunshot injuries, 1111–1113
Barbiturates, for crash-type anesthesia induction, in trauma patient, 1079–1080
Bargaining, client counseling about, in euthanasia, 1053
Basal cell tumors, cutaneous/subcutaneous, in cats, 965–966
Basic fibroblast growth factor, for impaired wound healing, 122
Basset Hound hereditary thrombopathia, transfusion for, 1392
Bathing, in feline grooming, 773–775
Bedlington terrier, chronic active hepatitis in, 391–392
copper-associated hepatopathy in, 411–412
Behavior modification drugs, for feline dermatoses, 990–992
Benzocaine-containing creams, for feline dermatoses, 1000
Benzodiazepines, endogenous, in hepatic encephalopathy, 341–343
for trauma patient, 1077–1078
for medium-fast anesthesia induction, 1080–1081
Benzoyl peroxide gel, for feline dermatoses, 985–986
Beta cell(s), altered glucose sensing in, in non-insulin-dependent diabetes mellitus, 557
degeneration of, in insulin-dependent diabetes mellitus, 554
Bicarbonate, for hepatic encephalopathy, 346
Bile acids, in hepatobiliary disease, 503–517
in liver disease diagnosis, 505–507
metabolism of, 504–505
physicochemical properties of, 504–505
tests of, 262–263
therapeutic potential of, 509–511
toxicity of, 507–509
Bile sludging, prevention of, bile acids for, 510
Biliary carcinoma, prevalence of, 422
radiographic appearance of, 426
treatment and prognosis in, 431
Biliary cirrhosis, 381–383
Biliary obstruction, causes of, 329
cholecytography of, 317
Biliary tract, diagnostic imaging of, 194–196
diseases of, 327–331
Bilirubin, conjugated, threshold for, 262
tests of, 261
Biologic sense, in observational studies, 12
Biopsy, 31–43
in surgical oncology, 224
of ulcerative skin lesion, in cats, 872
percutaneous needle, for acute liver failure, 448
principles of, 31–33
general complications, 33
indications, 31
specimen handling, 32–33
technical considerations, 32
techniques of, 33–41
catheter, 38–39
cutting-needle, 37–38
endoscopic, 38
excisional, 39
fine-needle, 33–37. See also Fine-needle biopsy.
intraoperative, 39–41
open incisional, 39
percutaneous, 33
Biopsy guns, automated, for liver biopsy, 282
Biopsy needle, in liver, sonogram of, 283
Biopt instrument, for liver biopsy, 282–283
Bite wounds, of joint, treatment of, 1215–1216
Bites, venomous, in cats, differential diagnosis of, 879
Bladder management, in spinal fracture/luxation, 1169
Bleeding, abdominal, counterpressure for, 1370
abnormal, diagnostic algorithm for, 1376
Bleeding profiles, in liver disease, 265
Blood, contaminated, and transfusion reaction in dogs, 1350
critical need for, 1365–1366
oxygen capacity of, 1433
Blood banking, 1231–1244
blood component preparation in, 1236–1237. See also Blood component(s).
blood storage in, 1257–1258
anticoagulant-preservatives for, selection of, 1263–1276
feline, 1313–1314
frozen plasma products, 1257–1258
platelet products, 1258
red blood cell storage lesion in, 1264–1266
red cell blood products, 1257
collection in, 1249–1252
additives and preservatives for, 1272
canine, 1249–1251
feline, 1251–1252, 1313–1314
hardware for, 1247, 1250
bags, 1248
bottles, 1247–1248
preparation for, 1248–1249
compatibility problems in, 1243
disease screening in, 1236
donor selection in, 1232, 1245–1247
canine, 1245–1246
feline, 1246–1247
equipment for, 1233
feline, 1234–1235
full service, 1234
general considerations in, 1236
plasma extractor for, 1255
quality control in, 1258–1260
frozen plasma products, 1259
platelet products, 1259–1260
red cell blood products, 1258–1259
separation options in, 1253-1254
separation techniques in, 1254-1257
canine, 1254-1256
cryoprecipitate and cryo-poor plasma, 1256
platelet products, 1255-1256
standard, 1254-1255
feline, 1256-1257

cryoprecipitate and cryo-poor plasma, 1256
platelet products, 1255-1256
standard, 1254-1255
feline, 1256-1257

Blood component(s), administration of, 1277-1290
indications for, 1279-1284
anemia, 1280-1282
hemostatic dysfunction, 1282-1283
hypoproteinemia, 1283
hypovolemia, 1283
leukopenia, 1283
monitoring of recipient, 1287-1289
step-wise approach to patient, 1285
characteristics of, 1277-1279
cryoprecipitate and cryo-poor plasma, 1279
fresh frozen plasma, 1279
frozen plasma, 1279
leukocytes, 1278-1279
packed red blood cells, 1278
platelet-rich plasma and platelet concentrate, 1278
whole blood, 1278
clinical use of, 1284
collection in, 1245-1261. See also under Blood banking.
dose and administration rates for, 1281
for cancer patients, concerns in, 1411-1412
graft-versus-host disease, 1412
transfusion reactions, 1411-1412
controversial issues regarding, 1413
future visions of, 1412-1413
bone marrow transplantation, 1412
hematopoietic growth factors, 1412-1413
indication by deficiency, 1411
for hemostatic disorders, 1387-1402
preparation of, 1236-1237
cryo-free plasma, 1238
cryoprecipitate, 1238
fresh frozen plasma, 1237-1238
packed red blood cells, 1237-1238
pretransfusion considerations in, 1284-1287
administration access and rate, 1286
amount needed, 1286
history, 1285
need for component administration, 1285
precautions, urgency of need, and contraindications, 1286
preparation of, 1286-1287
prophylaxis of hypersensitivity reactions, 1286-1287
simultaneous fluid therapy, 1287
type of loss and replacement needed, 1285
processing of, 1245-1261
red cells, quality control in, 1258-1259
storage of, 1257
role in cancer management, 1403-1416
separation of, 1233
storage of, 1245-1261. See also under Blood banking.
thirty with, guidelines for, 1281
reasons for, 1231
Blood crossmatching, in cats, 1310-1311
Blood donors, feline, characteristics of, 1311-1312
risks to, 1314-1215
Blood glucose. See also Glucose.
control of, clinical signs as indicators of, 571-572
equilibration of, 579
monitoring of, machines for, 579-580
recommendations concerning, 755-756
serial, problems with, 578-579
nadir of, target value for, 574
reduction of, in diabetic ketoacidosis, 644-646
regulation of, with surgery, in diabetes mellitus, 659
Blood glucose curve, in hospital setting, accuracy of, 757-758
interpretation of, 574-575
equilibration of blood glucose, 579
poor insulin activity, 575
short duration of insulin action, 577
twice-daily insulin injection, 577
with insulin therapy, 572-574
Blood glucose differential, calculation of, 574-575
Blood groups, canine, 1323-1332. See also Canine blood groups.
Blood loss, surgical, blood substitutes for, 1421
Blood products, for hemorrhage, in acute liver failure, 454
for shock, in trauma, 1021
preparation for administration, 1238-1243
cross matching for red blood cell transfusion, 1241-1243
feline whole blood, 1239
packed red blood cells, 1239
plasma products, 1239
typing and crossmatching, 1240
Blood substitutes, 1417-1439
clinical indications for, 1419-1422
ideal, 1421
research and development of, 1418
Blood transfusion(s), for hemostatic disorders, 1387-1402
Blood transfusion(s) (Continued)
small animal, additives used in, 1272-1273
formulation of, 1270
anticoagulant-preservatives used in, 1269-1271
anticoagulants used in, 1268-1269
to cats, 1315-1316
adverse reactions to, 1316-1321
Blood types, in cats, 1307-1310, 1312-1313
Body fluids, replacement of, in diabetic ketoacidosis, 641-642
Bone, composition of, 1061
osteosarcoma of, 191
physiology and healing of, radiation therapy and, 112
Bone grafts, for open fracture fixation, 1104
Bone marrow suppression, in cancer patient, blood components for, 1407
Bone marrow transplantation, future use of, for cancer patients, 1412
Borates, for fleas, in cats, 804
Bowen's disease, in cats, 962
Brain, and anesthesia drugs, in trauma patient, 1084-1085
diagnostic imaging of, 187-189
injury to, and alterations to intracranial pressure, effect on anesthetic management, 1074-1075
Breathing, examination of, in trauma, 1016
Bronchogenic carcinoma, metastatic, in cats, differential diagnosis of, 882
Buccal bleeding time, procedure for, 1375
Burmese cat, psychogenic alopecia in, 860
telogen effluvium in, 865
Burning mouth syndrome, with long-term diabetes mellitus, 732
Burns, in cats, differential diagnosis of, 878
Buspirone, for feline dermatoses, 991

Cachexia, in cancer, 62-64
Calcitonin, for hypercalcemia, 52-53
Caloric restriction, for insulin resistance, 707
Canadian hairless cat, 852
Cancer, and impaired wound healing, 109-129
anorexia/cachexia in, 62-64
as ecosystem, and consequences of subcutaneous therapy, 237
client counseling for, 17-29
avoiding information overload, 25
delivering bad news, 18-19
exhaustion of treatment options, 26-27
finishing up, 26
further diagnostic evaluation, 19-20
goals of treatment, 25-26
methods of therapy, 22-24
chemotherapy, 24
radiation therapy, 23-24
surgery, 22-23
presentation of therapeutic options, 20-22
fees, 22
perspective on treatment choices, 20-21
referrals, 21-22
decisions about therapy in, responsibility for, 28
definition of, 229-230
fluid and food selection in, 69-71
hematologic syndromes associated with, 1404
hepatic, metastatic, radiographic appearance of, 426
multimodality therapy for, 131
pathometabolic alterations in, 62
perioperative nutritional support in, 61-74
refeeding in, and feeding of tumor, 64
residual, control vs eradication of, 237-239
treatment of, hematologic abnormalities associated with, 1404
role of blood components in, 1403-1416
Candidiasis, with diabetes mellitus, 732-733
Canine blood groups, and immune-mediated transfusion reactions, 1336
importance in transfusion medicine, 1323-1332
in disease, 1330-1331
Canine osteosarcoma, 191
adjunct radiation therapy for, 142
micrometastatic disease in, 235
Canine thrombasthenic thrombopathia, transfusion for, 1392
Canine transfusion reactions, management of, 1333-1363. See also under Transfusion reactions.
Capillary ingrowth, and wound healing, 110
Capsular opacities, following canine cataract removal, 673
Capsulorrhaphy, and extracapsular suture stabilization, for coxofemoral joint reduction, 1183-1184
Carbohydrate, dietary, in diabetes mellitus, 589-590
metabolism of, in liver disease, 485-486
Carbon dioxide dissociation curve, oxygen partial pressure and, 1425
Card, for feline grooming, 769-770
Cardiac dysfunction, in trauma patient, anesthesia in, 1087
Cardiac injury, with thoracic trauma, 1038-1039
Cardiac tamponade, as oncologic surgical emergency, 206–209
clinical presentation and diagnosis of, 208
pathophysiology of, 206–208
surgical therapy and aftercare of, 208–209
with thoracic trauma, 1042–1043
Cardiovascular function, and anesthesia drugs, in trauma patient, 1085–1087
insufficiency of, with thoracic trauma, 1042
Cardiovascular system, support of, in acute liver failure, 449
Case-control studies, in oncology, 13
Cat(s), alopecia in, 851–870. See also Alopecia.
as blood donors, characteristics of, 1311–1312
risks to, 1314–1315
blood collection and storage from, 1313–1314
blood crossmatching in, 1310–1311
blood transfusion to, 1315–1316
adverse reactions to, 1316–1321
circulatory overload, 1320
electrolyte disturbances, 1320
hemolysis, 1317–1320
pyrexia, 1317
urticaria, 1320
vomiting, 1317
indications for, 1306–1307
blood types in, 1307–1310, 1312–1313
cutaneous and subcutaneous neoplasms in, 961–979
diabetes mellitus in, pathogenesis of, 527–552. See also under Diabetes mellitus.
eserinophil skin diseases in, 833–850.
See also Eosinophilic skin diseases.
fleas and pesticides in, 801–811
glucose tolerance test in, 530
grooming of, 767–778
hair of, fungal flora of, 902–903
hepatic neoplasia in, 419–435
hyperadrenocorticism in, insulin resistance vs, 701–702
hyperthyroidism in, insulin resistance vs, 702–703
neutrophil counts in, effect of granulocyte colony-stimulating factor on, 1447
nODULES and draining tracts in, 887–899
regional dermatoses in, 923–944. See also under Dermatoses.
urea cycle of, 369
with liver disease, homemade diets for, 495
Catabolism, in cancer, consequences of, 64–65
Catheter biopsy, 38–39
Cellular microaggregates, in autotransfusion, 1301
Cellular resistance, and chemotherapy failure, 136–137
Central nervous system, examination of, in trauma, 1016–1017
Cephalosporins, for feline dermatoses, 983
Cerebral edema, in fulminant hepatic failure, 351
Ceruminous gland adenocarcinoma, in cats, 964–965
Chelating agents, for copper-associated hepatopathies, 408–410
Chemical agents, and acute liver failure, 438–439
Chemotherapeutic agents, for feline dermatoses, 994–996
Chemotherapy, 131–146
adjuvant, 133–134
for tumor metastases, obstacles to success in, 236
administration of, 134–135
as cancer therapy, 24
neoadjuvant, 133
simultaneous, 134
toxicity of, 135–136
treatment considerations for, 132
treatment failure with, sources of, 136–137
Chenodeoxycholate, for cholelithiasis, 509–510
Chenodeoxycholic acid, toxicity of, 509
Cholangiohepatitis, feline, 375–385
lesions of, 299
nonsuppurative, 379–380
portal fibrosis of, 380
suppurative, 376–379
Cholangitis, emphysematous, 311
lesions of, 299
nonsuppurative, 379–380
suppurative, 376–379
Cholecytitis, acute, ultrasound scan of, 328
Cholecystography, 315–317
Cholelithiasis, 328–329
bile acids for, 509–510
Cholescintigraphy, biliary, in suppurative cholangitis/choleiohepatitis, 377
Cholestasis, and hyperbilirubinemia, 262
bile acids and, 507–509
enzymes indicative of, 259–260
prevention of, by ursodeoxycholate, 512
Cholestasis (Continued)
with glipizide, for feline diabetes mellitus, 608
Cholesterol, in liver disease, 265–266
Chronic inflammatory disease, anemia in, blood components for, 1404
Chronic pain, in surgical oncology patient, therapy for, 90–92
Chrysotherapy, for feline dermatoses, 996
Chylothorax, with thoracic trauma, 1034
Circulation, with gunshot injuries, 1116
Circulatory overload, with canine blood transfusion, 1351–1352
with feline blood transfusion, 1320
Cirrhosis, biliary, 381–383
hepatic, ultrasound scan of, 323
Citrate-phosphate-dextrose, in small animal transfusions, 1271
Citrate-phosphate-dextrose-adenine, in small animal transfusions, 1271
Citrate toxicity, with canine blood transfusion, 1353–1354
Client counseling, in orthopedic emergencies, 1047–1058
Client grief, in euthanasia, 1053–1055
Clinical pathologic testing, in feline dermatology, 795–797
Clipping, in feline grooming, 771, 773
Clot formation, in autotransfusion, 1301
Coagulation, maintenance of, in resuscitation from hemorrhage, red blood cells in, 1372–1373
studies of, in acute liver failure, 444–445
in liver disease, 265
Coagulation disorders, as paraneoplastic syndromes, perioperative management of, 46–51
in cancer patient, blood components for, 1410–1411
in diabetes mellitus, 633–634
transfusion for, 1394–1399
acquired inhibitors, 1398–1399
acute pancreatitis, 1399
anti-vitamin K intoxication, 1397
canine hyperadrenocorticism, 1399
disseminated intravascular coagulation, 1397–1398
dysfibrinogenemia, 1395
Factor VII deficiency, 1395
Factor X deficiency, 1396–1397
Factor XII deficiency, 1397
hemophilia, 1395–1397
hypofibrinogenemia, 1394–1395
liver disease, 1398
nephrotic syndrome, 1398
prothrombin deficiency, 1395
vitamin K-responsive coagulopathy, 1397

Coagulation factors, critical need for, 1375–1385
in disseminated intravascular coagulation, 1380–1385
secondary survey in, 1374–1376
emergency laboratory assessment, 1374–1375
history, 1374
laboratory testing, 1375–1376
physical examination, 1374
therapeutics in, 1376–1378
Coagulopathy(ies), as autotransfusion complication, 1297–1298
in feline idiopathic hepatic lipidosis, 365
with canine blood transfusion, 1354
Coccidian diseases, in cats, cutaneous manifestations of, 949–950
Cocker spaniel, chronic active hepatitis in, 392
Codeine, for chronic pain, in surgical oncology patient, 90–91
Cohort studies, in oncology, 13
Colchicine, for long-term hepatitis, 395
Cold, application of, in trauma, 1026
Cold agglutinin disease, in cats, 877
Collagen synthesis, and wound healing, 110
Collagenolytic granuloma, in cats, 931–932
Colloid osmotic pressure, and hemoglobin modifications, 1426–1427
Colloid solutions, for shock, in trauma, 1021
Colonoscopy, oncologic applications of, 174
Coma, nonketotic hyperosmolar, diabetic, emergency therapy of, 646–648
Combs, for feline grooming, 769–771
Common bile duct, dilatation of, 330
Communication/support, in orthopedic emergencies, 1048–1049
Computed tomography, as diagnostic imaging modality, 185–186
Consistency, in observational studies, 12
Constipation, with long-term diabetes mellitus, 737
Copper, accumulation of, and liver disease, 399
breeds associated with, 400
chelators of, 410
distribution of, 401
food content of, 400, 406
hemostasis of, 401
metabolism of, 400–402
abnormal, 402–403
in liver disease, 490
toxicity of, 403
in liver disease, management of, 498
transport in body, 402
Copper-associated hepatopathies, 399–417
clinical picture of, 403–404
diagnosis of, 404–405
emergency treatment of, 411
guidelines for therapy, 414–415
treatment of, 405–411
Copper storage disease, and acute liver failure, 441
Corneal edema, following canine cataract removal, 673
Cortical bone loss, in gunshot injury, 1121
Corticosteroids, for biliary cirrhosis, 383
for chronic pain, in surgical oncology patient, 91–92
for feline eosinophilic skin diseases, 838
for feline psychogenic alopecia, 861
for hypercalcemia, 52
for long-term hepatitis, 394–395
for spinal cord trauma, 1151
guidelines for, 1152
for spinal fracture/luxation, complications of, 1170
for suppurative cholangitis/cholangitis-hepatitis, 377
topical, following canine cataract removal, 671
Cowpox virus infection, cutaneous, in cats, 893
Coxofemoral joint, reduction of, 1180–1182
DeVita pin for, 1180–1182
Ehlmer sling for, 1180–1181
fascia lata loop stabilization for, 1185
flexible external fixator for, 1182–1183
greater trochanter transposition for, 1183–1184
ischioilial pinning for, 1180–1182
toggle-pin fixation for, 1184–1185
transarticular pinning for, 1185
traumatic luxation of, aftercare of, 1186
complications of, 1186
diagnosis of, 1176–1178
prognosis in, 1186
treatment of, 1178–1185
closed reduction, 1179–1183
open reduction and stabilization, 1183–1185
with avulsion fracture, 1178
Cranial nerve palsies, with long-term diabetes mellitus, 725
Critical care medicine, transfusion therapy in, 1365–1385
Crossmatching, in prevention of canine hemolytic transfusion reaction, 1343–1344
Cross-sectional studies, in oncology, 12–13
Crusting dermatoses, in cats, diagnostic procedures in, 780
of face, 924–928
Cryoprecipitate, characteristics of, 1279
Cryptococcosis, cutaneous, in cats, 896
Crystalloid fluids, for shock, in trauma, 1020
Cushing’s syndrome, and insulin resistance, management of, 705–706
Cutaneous disease, in cats, antibiotics for, 981–986
Cutaneous manifestations, systemic diseases with, 945–959
Cyclophosphamide, for feline dermatoses, 995
Cyclosporine, for feline dermatoses, 996
Cystic duct, dilatation of, 330
Cytology, in feline dermatology, 789–790
Cytopenias, prevention of, with granulocyte colony-stimulating factor, 1446
Cytotoxic chemotherapy, adjuvant, for tumor metastases, obstacles to success in, 236
and impaired wound healing, in cancer patient, 109–129
Debridement, and wound healing, 110
Degloving injury, 1200
treatment of, 1216–1217
Dehydration, with diabetic ketoacidosis, 619–620
Dehydrocholate, for bile sludging prevention, 510
Delayed union, in open fracture, management of, 1107
Demodiconis, in cats, and excessive shedding of whole hairs, 866–867
Denial, client counseling about, in euthanasia, 1053
Depression, client counseling about, in euthanasia, 1054–1055
Dermatitis, in cats, actinic, differential diagnosis of, 878
allergic miliary, 814–816
eosinophilic, 930–933, 939
irritant contact, differential diagnosis of, 878
papular, in mosquito-bite hypersensitivity, 839
solar, 828–830, 926
Dermatology, feline, diagnostic procedures in, 779–799. See also Feline dermatology.
Dermatophyte vaccine, experimental killed, immune response of kittens to, 907–908
Dermatophytosis, feline, 821–823, 901–921
and excess hair loss, 857–858
diagnostic tests for, fungal cultures, 909–910
hair shaft examination for fungal elements, 909
Dermatophytosis (Continued)
Wood’s lamp examination, 908–909
epidemiologic aspects of, 901–904
fungal flora of cat hair, 902–903
zoontic considerations, 903–904
immunology of, 906–908
pathogenesis of, 904–905
treatment of, 910–916
controversial, 916–919
fixed treatment schedules, 916–917
fungal vaccines, 917–919
dip therapy, 911–913
environmental decontamination, 915–916
hair coat clipping, 911
monitoring of, 915
systemic therapy, 913–915
topical antifungal therapy, 913
topical shampoo, 911–913

Dermatoses, feline, 813–831
allergic, 814–820
atopy, 818–820
autoimmune, 825–828
pemphigus erythematous, 828
pemphigus foliaceus, 825–828
food allergy, 816–818
infectious, 820–823
of face, nodular/ulcerative, 929
of feet, 936–940
of pinnae, 934–936
parasitic, 823–825
regional, 923–944
therapy for, 981–1005
antibiotics, 981–986
benzyol peroxide gel, 985–986
cephalosporins, 983
fluoroquinolones, 984–985
lincomamides, 983–984
macrolides, 983
metronidazole, 985
mupirocin, 985
penicillins, 981–982
potentiaded sulfas, 984
tetracyclines, 983
antifungals, 986–987
antihistamines, 989–990
antileprosy drugs, 987
antiparasite drugs, 987–988
antivirals, 989
behavior modification drugs, 990–992
chemotherapeutic agents, 994–996
fatty acids, 992
food elimination trials/
hyposalergenic diets, 999
hyposensitization/immunotherapy, 999
immunomodulating drugs, 994
immunosuppressive agents, 994–996
mechanical devices, 998–999
progestogons, 992–993
retinoids, 996–998
steroids, 993–994
topical agents, 1000

Descriptive studies, in oncology, 11
DeVita pin, for coxofemoral joint reduction, 1180–1182.

Diabetes mellitus, canine, blood glucose control in, clinical signs of, 571–572
clinical presentation of, 565–568
diagnosis of, 563–570
establishment of, 568–569
historic findings in, 565
hyperosmolar coma in, 567
insulin-dependent, 554–556
insulin resistance in, 691–713. See also Insulin resistance.
long-term monitoring of, 571–584
non-insulin-dependent, 556–558
ocular manifestations of, 661–676. See also Diabetic cataracts.
pathophysiology of, 553–561
physical examination findings in, 566–567
recommended macronutrient content in, 592–593
secondary, 558
unregulated, algorithm for, 580
clinical signs of, pathophysiology of, 563–564
complicated, clinical signs of, 567–568
concurrent disease with, 617–619
dietary recommendations for, 593–595
defects in host defenses in, 744
diagnosis of, 563–570
effect on gastrointestinal system, 733
feline, blood glucose control in, clinical signs of, 571–572
classification of, 599–601
insulin-dependent, 600
non-insulin-dependent, 600–601
clinical presentation of, 565–568
diagnosis of, 563–570, 603–605
establishment of, 568–569
insulin secretagogue testing, 603–605
pretreatment evaluation, 603
difficulty of regulating, 758–759
etiology and pathogenesis of, 601–602
islet-specific amyloid, 601–602
obesity, 601
pancreatic histopathology, 602
historic findings in, 565
hyperosmolar coma in, 567
insulin resistance in, 691–713. See also Insulin resistance.
long-term monitoring of, 571–584
non-insulin-dependent, treatment of, 605–613
glipizide, 599–615
oral hypoglycemic medications, 606–610
obesity and, 532–533
pathogenesis of, 527–552
amylin and amyloid in, 533–542
factors in, 544
physical examination findings in, 566–567
primary, type 1, 528
type 2, 528–529
 genetic predisposition in, 529
human vs, 528–529
impaired insulin secretion in, 529–532
insulin resistance in, 532
recommended macronutrient content in, 592–593
resolution of, 759
secondary, 528
terminology in, 527–528
treatment of, perspectives in, 543–545
types of, comparative aspects of, 600
unregulated, algorithm for, 580
general principles in, 553–554
hematologic complications of, 625–637.
See also Hematologic complications.
in cats, and excessive shedding of whole
hairs, 863
cutaneous manifestations of, 953
in thin animal, high fiber diet in, 759
infections associated with, 744
insulin-dependent, common questions concerning, 753–759
home management of, concerns re­garding, 754–755, 757
insulin therapy for, 677–689. See also In­sulin therapy.
ketoacidotic, clinical signs of, 567–568
long-term complications of, 715–751
gastrointestinal diseases, 731–739
hepatic/pancreatic disease, 739–742
pathogenesis of, 716–718
micronutrient composition in, 593
nutritional therapy for, 585–597. See also Nutritional therapy.
pathogenesis of, 553
regulation of, difficulties in, reasons for, 575
severe, complications and concurrent dis­ease with, 617–624
signalment in, 565
surgery in, 651–660
effects on patient, 651–652
 elective, 653–654
emergency, 654–655
major nonemergency, 654
postoperative considerations in, 658–659
preoperative considerations in, 652–653
special considerations in, 655–657
transient, impaired glucose tolerance and, 542–543
uncomplicated, clinical signs of, 565–566
vascular changes in, 717
Diabetic cataracts, in dogs, 661–676
cell membrane and osmotic changes in, 662–664
clinical evaluation of, 666–667
glycosylation-induced changes in, 665
oxidative stress in, 665–666
pathophysiology of, 662–666
treatment of, 667–674
complications of, 672–674
future developments in, 674
lensectomy, 669–671
 extracapsular extraction, 670–671
phacoemulsification, 669–670
postsurgical management of, 671–672
postsurgical outcome in, 672–674
 presurgical preparation for, 667–669
uveitis with, 668
vacuole formation in, 667
Diabetic crises, emergency therapy of, 639–650
Diabetic diarrhea, 736–737
Diabetic ketoacidosis, complications and concurrent disease with, 617–624
emergency therapy of, 641–646
identification of underlying factors, 641
protocol for, 643
reduction of serum glucose concentra­tion, 644–646
replacement of body fluids, 641–642
restoration of electrolyte and acid-base balances, 642–644
initial presentation and therapy of, com­plications associated with, 619–623
pathophysiology of, 564
Diabetic nephropathy, correlation with diabetic retinopathy, 723
with long-term diabetes mellitus, 721–723
Diabetic retinopathy, in dogs, 661
with long-term diabetes mellitus, 718–721
clinical findings in, 718
pathogenesis of, 719–721
 Diagnostic imaging, 183–203
anatomic sites of, 187–193
abdominal mass, 193–200
brain and spinal cord, 187–189
algorithm for, 188
extremity tumors, 189–192
nasal and oral cavity, 189
 thorax, 192–193
Diagnostic imaging (Continued)
modalities of, 183-187
computed tomography, 185-186
magnetic resonance imaging, 186-187
nuclear medicine, 186
radiography, 184, 186
ultrasonography, 184-185
Diagnostic testing, in trauma, 1018-1019
Diaphragmatic hernia, with thoracic trauma, 1034-1035
Diarrhea, diabetic, 736-737
Diazepam, for feline dermatoses, 990
for hepatic encephalopathy, 346
Diazoxide, for insulinoma, 55
Diestrus, and canine insulin resistance, management of, 706
Diet, for copper-associated hepatopathies, 406-408
for feline idiopathic hepatic lipidosis, 362-366
calculation of, 364
for hepatic encephalopathy, 348-351
for long-term hepatitis, 395
Dietary hypersensitivity, and excess hair loss in cats, 858
Dietary trials, in feline dermatology, 795
Dimethyl sulfoxide, for spinal cord trauma, 1152
Dip therapy, for feline dermatophytosis, 911-913
Diphosphonates, for hypercalcemia, 52
Discharge planning, client counseling about, in orthopedic emergencies, 1052-1053
Disease transmission, with canine blood transfusion, 1356-1357
Dissection, in surgical oncology, 99-102
Disseminated intravascular coagulation, anticipation of, 1379
as paraneoplastic syndrome, perioperative management of, 49-50
diagnosis of, 1380-1381
indicators of, 1380
stimuli for, 1379
therapy for, 1381-1383
transfusion for, 1397-1398
with transfusion, 1378-1383
Diuretics, for ascites, in portal hypertension, 476
for biliary cirrhosis, 382
for hypercalcemia, 52
Doberman pinscher, chronic active hepatitis in, 391
copper-associated hepatopathy in, 413-414
Dog(s), chronic active hepatitis in, 393
copper-associated hepatopathies in, 399-417
diabetes mellitus in. See under Diabetes mellitus.
hepatic neoplasia in, 419-435
hyperadrenocorticism in, insulin resistance vs, 699-701
hypothyroidism in, insulin resistance vs, 703
lymph nodes of, 148-150
neutrophil counts in, effect of granulocyte colony-stimulating factor on, 1447-1448
transfusion reactions in, management of, 1333-1363
with liver disease, homemade diets for, 495
Dog erythrocyte antigen (DEA) system, 1324
classifications in, 1325-1327
identification of universal donors with, 1328
laboratories testing with, 1329
typing and donor selection with, 1327-1330
Dog foods, macronutrient content of, 593
Dorsal spinal plating, for spinal fracture/luxation stabilization, 1166-1167
Dose response, in observational studies, 12
Doxorubicin treatment, neutrophil counts in, effect of granulocyte colony-stimulating factor on, 1448
Draining tracts, in cats, 887-889
Drug(s), and acute liver failure, 438-440
for feline idiopathic hepatic lipidosis, 365
Drug administration, insulin resistance vs, 704
Drug-induced thrombocytopenia, transfusion for, 1390
Drug-induced thrombopathia, transfusion for, 1392
Drug reactions, in cats, differential diagnosis of, 877
Dryer, for feline grooming, 769, 771
Dust mite allergens, positive skin response to, in cats, 856
Dysfibrinogenemia, transfusion for, 1395
Ear cleaner, for feline grooming, 771
Economics, client counseling about, in orthopedic emergencies, 1051-1052
Ehlmer sling, for coxofemoral joint reduction, 1180-1181
Elbow, traumatic luxation of, 1190-1195
aftercare of, 1193-1194
complications of, 1194
diagnosis of, 1191-1192
prognosis in, 1195
spica splint for, 1194
treatment of, 1192-1193
Electric clippers, for feline grooming, 771
Electrocardiogram, in trauma, 1019
Electrofulguration, of melanoma, 101
Electrolyte(s), disturbances of, with feline
blood transfusion, 1320
imbalance of, and hepatic encephalopa-
thy, 345
management of, with surgery, in diabe-
etes mellitus, 658
restoration of balance in, in diabetic keto-
acidosis, 642–644
solutions of, for shock, in trauma, 1021–
1022
Embden-Meyerhof pathway, in red blood
cell metabolism, 1265
Emergency patient, autotransfusion in,
1291–1304
advantages of, 1293–1294
complications of, 1296–1302
history of, 1291–1293
methods of, 1294–1296
transfusion in, 1365–1385
Enalopril, for biliary cirrhosis, 382
Encephalopathy, hepatic, 337–355. See also
Hepatic encephalopathy.
End points, in surgical oncology,
definition of, 224–225
Endocrine diseases, in cats, cutaneous
manifestations of, 950–954
Endoscopy, 167–181
biopsy with, 38
oncologic applications of, equipment for,
167–169
examination in, 168
gastrointestinal, 169–174
colon, 174
esophagus, 169–170
small intestine, 172–174
stomach, 170–172
laparoscopy, 178–180
neoplasms diagnosed by, 179
respiratory, 175–178
larynx/trachea, 175
nasal, 176–178
pulmonary, 175–176
Enemas, for hepatic encephalopathy, 346
Energy requirements, calculation of,
perioperative, 66–67
in liver disease, 491–492
Enteral feeding, for cancer patient, liquid
formula for, 71
perioperative, 67–69
Environmental decontamination, for feline
dermatophytosis, 915–916
Eosinophilic skin diseases, feline, 833–850
categories of, 834
dermatitis, 930–933, 939
granuloma, 840–845
diagnosis of, 843–844
therapeutic management of, 844–845
indolent ulcer, 845–848
mosquito-bite hypersensitivity,
838–840
plaques, 835–837, 835–838, 930
diagnosis of, 836–837
therapeutic management of, 837–838
Epidemiology, and veterinary oncologist,
1–15
Epidermal growth factor, for impaired
wound healing, 119–121
Epidermis, fine-needle biopsy of, 34
Epidural analgesia, for pain, in surgical
oncology patient, 89
in trauma patient, 1083–1084
Epithelial tumors, in cats, 961–966
Epitheliogenesis imperfecta, in cats,
differential diagnosis of, 879
Epitheliomatrophic lymphoma, in cats,
differential diagnosis of, 881–882
Erck arch bar with acrylic, for mandibular
fracture fixation, 1139, 1142
Erosive skin disease, in cats, 871–885
Erythema multiforme, in cats, differential
diagnosis of, 877
Erythrocyte(s), abnormalities of, in
diabetes mellitus, 627–631
membrane and deformability,
630–631
metabolic, 629–630
in liver disease, 266
Erythrocyte antigen system, canine,
1324–1327. See also Dog erythrocyte
antigen (DEA) system.
Erythrocyte survival curves, in transfused
cats, 1319
Erythropoietin, as hematopoietic growth
factor, 1442–1444
use in veterinary medicine, 1443–1444
Esophageal disorders, with long-term
diabetes mellitus, 733, 735
Esophageal masses, diagnostic imaging of,
algorithm for, 197
Esophagostomy tube, selection and use of,
70
Esophagus, endoscopy of, oncologic
applications of, 169–170
Etomidate, for crash-type anesthesia
induction, in trauma patient, 1080
Etretinate, for feline dermatoses, 997–998
Eumycotic mycetomas, cutaneous, in cats,
896
Euthanasia, and client grief, counseling
about, 1053–1055
Excisional biopsy, 39
Exercise, in insulin-dependent diabetes
mellitus, 756
Experimental studies, in oncology, 14
Explanatory studies, in oncology, 11–12
External coaptation, for spinal fracture/
luxation stabilization, 1162
External skeletal fixation, for gunshot
injury, 1121–1122, 1124
External skeletal fixation (Continued)
for mandibular fractures, 1138–1142
for open fractures, 1102–1103
for spinal fracture/luxation stabilization, 1162
Extravehicular shunt, appearance of, 332–333
Extremity tumors, diagnostic imaging of, 189–192
Eye lubricant, for feline grooming, 771

Face, of cat, indolent ulcer of, 846
nodular/ulcerative dermatoses of, 929
pruritus of, 928
skin disorders of, 923–933
Factor VII deficiency, transfusion for, 1395
Factor X deficiency, transfusion for, 1396–1397
Factor XII deficiency, transfusion for, 1397
Fascia lata loop stabilization, for coxofemoral joint reduction, 1185
Fat, dietary, in diabetes mellitus, 589
in hepatic encephalopathy, 350
metabolism of, in liver disease, 486–487
Fatty acids, consumption of, in liver disease, 497
for feline dermatoses, 992
in feline idiopathic hepatic lipidosis, impaired oxidation, 369–371
increased mobilization, 367–368
Fecal flotation, in feline dermatology, 796
Feeding management, in liver disease, 494–496
Feeding tubes, selection and use of, 70
Feline dermatology, diagnostic procedures in, 779–799
acetate tape preparations, 782–783
bacterial culture and susceptibility testing, 788–789
clinical pathologic testing, 795–797
cytology, 789–790
dietary trials, 795
fetal flotation, 796
fungal culture, 786–788
history, 780–781
immunofluorescence/
immunohistochemical staining, 791
intradermal skin test, 791–793
physical and dermatologic examination, 781
potassium hydroxide preparations, 783–784, 786
response to treatment, 796–798
scraping/impression smears for yeast, 784–785
serologic tests for allergies, 794–795
signalment, 779–780
skin biopsy, 790–791

skin scrapings, 781–782
Wood’s lamp examination, 785–786
Feline dermatophytosis, 901–921. See also under Dermatophytosis.
Feline dermatoses, therapy for, 981–1005. See also Dermatoses.
Feline immunodeficiency virus, cutaneous manifestations of, 947
Feline leukemia virus, cutaneous manifestations of, 946–947
Feline transfusion medicine. See under Cats.
Feline upper respiratory viruses, cutaneous manifestations of, 947–948
Femoral condyle, gunshot injury of, 1213
Fiber, dietary, in diabetes mellitus, 590–592
Fibrinolysis, abnormalities of, in diabetes mellitus, 633–634
Fibroplasia, and wound healing, 110
Fibrosarcomas, cutaneous subcutaneous, in cats, 966–969
Fine-needle aspiration, for acute liver failure, 447–448
Fine-needle biopsy, 33–37
accuracy of, 33–36
aspiration vs nonaspiration, 36–37
efficacy of, 36
of mammary gland tumors, 37
Firearms, injuries by, 1113–1114
Flea(s), in cats, 801–811
biology of, 801–802
control of, 806–808
pesticides for, 802–807. See also Pesticides.
Flea bite hypersensitivity, in cats, 814–816
and excess hair loss, 853–854
Flexible external fixator, for coxofemoral joint reduction, 1182–1183
Flopped-eared cats, dermatoses of, 936
Fluid(s), administration of, in open fracture management, 1096–1097
in trauma, 1019–1023
management of, with surgery, in diabetes mellitus, 658
therapy with, for acute liver failure, 451–452
for hepatic encephalopathy, 346
Flumazenil, for hepatic encephalopathy, 453–454
Fluoroquinolones, for feline dermatoses, 984–985
5-Fluorouracil, for feline dermatoses, 996
Fluoxetine, for feline dermatoses, 991
Folic acid analogs, effects on wound healing, 116
Folliculitis, in cats, bacterial, 820–821
and excessive shedding of whole hairs, 866
facial, 924–926
Food(s), copper content of, 400, 406
Food allergy, in cats, and dermatoses, 816–818
Food dose, perioperative, calculation of, 67
Food elimination trials, for feline dermatoses, 999
Foot (feet), of cat, cutaneous disorders of, 936–940
eosinophilic granuloma of, 841
Fracture(s), biomechanics of, 1061–1062
complications of, 1071
configuration of, problems posed by, 1065
definition of terms in, 1063
description of, 1062–1065
algorithm for, 1064
implications for management, 1064
diagnosis of, 1060–1061
fixation devices for, 1067
complications with, 1068
forces involved in, 1062
management of, decisions in, 1059–1072
open, management of, 1093–1110. See also Open fracture.
perioperative decisions in, 1069–1070
postoperative decisions in, 1070–1071
preoperative decisions in, how to repair, 1067–1069
possibility of repair, 1066
when to repair, 1066–1067
reduction of, in penetrating joint injuries, 1211–1212
stabilization of, in penetrating joint injuries, 1211
temporary, 1065–1066
with thoracic trauma, management of, 1031–1046
Fresh frozen plasma, preparation of, 1237–1238
Frostbite, in cats, differential diagnosis of, 878
Fructosamine, long-term glucose monitoring with, 581–583
Fungal culture, in feline dermatology, 786–788
in feline dermatophytosis, 909–910
Fungal infections, and acute liver failure, 440
cutaneous, in cats, 893–894
Fungal vaccines, for feline dermatophytosis, 917–919
Furosemide, for ascites, in portal hypertension, 477
for biliary cirrhosis, 382
Glaucoma transferase, in cholestasis, 260
Gastric disorders, with long-term diabetes mellitus, 733, 735–736
Gastric neoplasia, as oncologic surgical emergency, 217
deroscopy of, 171
Gastric surgery, in oncology patient, infection with, 82
Gastroenterologic oncologic emergencies, 215–218
clinical presentation and diagnosis of, 216
pathophysiology of, 215–216
surgical therapy and aftercare of, 216–218
Gastrointestinal bleeding, and hepatic encephalopathy, 344
in acute liver failure, protective agents for, 454–455
Gastrointestinal diseases, with long-term diabetes mellitus, 731–739
treatment of, 738–739
Gastrointestinal endoscopy, oncologic applications of, 169–174
Gastrointestinal side effects, of glipizide, 608
Gastrointestinal tract, diagnostic imaging of, 197–198
Gastroscopy, oncologic applications of, 172
Gastrostomy tube, selection and use of, 70
General anesthesia, in mandibular fracture, 1129
Genital surgery, in oncology patient, infection with, 83
Gingival disease, with long-term diabetes mellitus, 732
Glioma, canine, imaging of, 188
Glipizide, for feline diabetes mellitus, 599–615
clinical outcomes with, 610–611
dietary therapy with, 609–610
goals of therapy with, 609
insulin replacement with, 613
monitoring response to, 611–613
patient selection for, 609
predictors of response to, 607–608
side effects of, 608
treatment protocol for, 609
Glomerular disease, in diabetic nephropathy, 721
Glucagon-like peptide-1, and impaired insulin secretion, 531
for feline diabetes mellitus, 543
Glucocorticoids, and canine insulin resistance, management of, 706
and feline insulin resistance, 705
effects on wound healing, 116–117
for insulinoma, 55
Glucocorticosteroids, for feline dermatoses, 993–994

Gallbladder, diseases of, 327–331
Gamma-aminobutyric acid, in hepatic encephalopathy, 341–342
Gamma glutamyltransferase, in cholestasis, 260
Gastric disorders, with long-term diabetes mellitus, 733, 735–736
Gastric neoplasia, as oncologic surgical emergency, 217
deroscopy of, 171
Gastric surgery, in oncology patient, infection with, 82
Gastroenterologic oncologic emergencies, 215–218
clinical presentation and diagnosis of, 216
pathophysiology of, 215–216
surgical therapy and aftercare of, 216–218
Gastrointestinal bleeding, and hepatic encephalopathy, 344
in acute liver failure, protective agents for, 454–455
Gastrointestinal diseases, with long-term diabetes mellitus, 731–739
treatment of, 738–739
Gastrointestinal endoscopy, oncologic applications of, 169–174
Gastrointestinal side effects, of glipizide, 608
Gastrointestinal tract, diagnostic imaging of, 197–198
Gastroscopy, oncologic applications of, 172
Gastrostomy tube, selection and use of, 70
General anesthesia, in mandibular fracture, 1129
Genital surgery, in oncology patient, infection with, 83
Gingival disease, with long-term diabetes mellitus, 732
Glioma, canine, imaging of, 188
Glipizide, for feline diabetes mellitus, 599–615
clinical outcomes with, 610–611
dietary therapy with, 609–610
goals of therapy with, 609
insulin replacement with, 613
monitoring response to, 611–613
patient selection for, 609
predictors of response to, 607–608
side effects of, 608
treatment protocol for, 609
Glomerular disease, in diabetic nephropathy, 721
Glucagon-like peptide-1, and impaired insulin secretion, 531
for feline diabetes mellitus, 543
Glucocorticoids, and canine insulin resistance, management of, 706
and feline insulin resistance, 705
effects on wound healing, 116–117
for insulinoma, 55
Glucocorticosteroids, for feline dermatoses, 993–994

Gallbladder, diseases of, 327–331
Gamma-aminobutyric acid, in hepatic encephalopathy, 341–342
Gamma glutamyltransferase, in cholestasis, 260
Gastric disorders, with long-term diabetes mellitus, 733, 735–736
Gastric neoplasia, as oncologic surgical emergency, 217
deroscopy of, 171
Gastric surgery, in oncology patient, infection with, 82
Gastroenterologic oncologic emergencies, 215–218
clinical presentation and diagnosis of, 216
pathophysiology of, 215–216
surgical therapy and aftercare of, 216–218
Gastrointestinal bleeding, and hepatic encephalopathy, 344
in acute liver failure, protective agents for, 454–455
Gastrointestinal diseases, with long-term diabetes mellitus, 731–739
treatment of, 738–739
Gastrointestinal endoscopy, oncologic applications of, 169–174
Gastrointestinal side effects, of glipizide, 608
Gastrointestinal tract, diagnostic imaging of, 197–198
Gastroscopy, oncologic applications of, 172
Gastrostomy tube, selection and use of, 70
General anesthesia, in mandibular fracture, 1129
Genital surgery, in oncology patient, infection with, 83
Gingival disease, with long-term diabetes mellitus, 732
Glioma, canine, imaging of, 188
Glipizide, for feline diabetes mellitus, 599–615
clinical outcomes with, 610–611
dietary therapy with, 609–610
goals of therapy with, 609
insulin replacement with, 613
monitoring response to, 611–613
patient selection for, 609
predictors of response to, 607–608
side effects of, 608
treatment protocol for, 609
Glomerular disease, in diabetic nephropathy, 721
Glucagon-like peptide-1, and impaired insulin secretion, 531
for feline diabetes mellitus, 543
Glucocorticoids, and canine insulin resistance, management of, 706
and feline insulin resistance, 705
effects on wound healing, 116–117
for insulinoma, 55
Glucocorticosteroids, for feline dermatoses, 993–994
Glucose. See also Blood glucose.

for hepatic encephalopathy, 346

metabolism of, in lens, in diabetes mellitus, 662–663

serum, in liver disease, 264

Glucose meters, for blood glucose monitoring, 579–580

Glucose monitoring, long-term, with fructosamine, 581–583

with glycosylated hemoglobin, 581–583

Glucose tolerance, impaired, and amount of pancreatic amyloid deposition, 535–536

and transient diabetes, 542–543

test of, amylin concentration during, 540

Glucose toxicity, and impaired insulin secretion, 531–532

in feline diabetes mellitus, 605

Glutamate, in hepatic encephalopathy, 341

Gluten-induced enteropathy, insulin-dependent diabetes mellitus and, 737

Glycogen, metabolism of, effect of amylin on, 539

Glycosylated hemoglobin, long-term glucose monitoring with, 581–583

Graft-versus-host disease, in blood component therapy, in cancer patients, 1412

Granulocyte colony-stimulating factor, as hematopoietic growth factor, 1444–1449

effect on neutrophil counts, 1445–1446

prevention of treatment-induced cytopenias with, 1446

use in veterinary medicine, 1445–1449

Granulocyte counts, increase in, with granulocyte-macrophage colony-stimulating factor, 1450

Granulocyte-macrophage colony-stimulating factor, as hematopoietic growth factor, 1449–1451

use in veterinary medicine, 1450–1451

Granuloma pyogranuloma syndrome, sterile, in cats, 929–930

Greater trochanter transposition, for coxofemoral joint reduction, 1183–1184

Grief, with euthanasia, client counseling about, 1053–1055

Griseofulvin, for feline dermatophytosis, 914

for feline dermatoses, 987

Grooming, feline, 767–778

bathing, 773–775

clipping, 773

equipment for, 769–773

restraint in, 768–769

Growth factors, for cancer, pharmacologic modulation by, 109–129

for impaired wound healing, 118–122

hematopoietic, 1441–1455. See also Hematopoietic growth factors.

Growth hormone, overproduction of, insulin resistance vs, 697–699

Gum, removal of, in feline grooming, 776

Gunshot injury(ies), 1111–1126

ballistics and, 1111–1113

complications of, 1124–1125

evaluation of patient with, 1116–1117

fracture considerations in, 1119

fracture fixation in, 1119–1122

of femoral condyle, arthrodesis for, 1213

of radius and ulna, 1122, 1200

tissue damage of, 1114–1116

to joints, 1122–1124

treatment of, 1217–1218

treatment of, 1117–1119

antibiotic, 1118

cleansing, 1118

surgical, 1118

Haemonetics Cell Saver, schematic of, 1293

Hair coat, in cats, clipping of, for dermatophytosis, 911

production failure/abnormalities of, 851–852

Hair shaft examination, for fungal elements, in feline dermatophytosis, 909

Haloperidol, for feline dermatoses, 991

Halothane, for anesthesia maintenance, in trauma patient, 1081

Hand cleaner, waterless, for feline grooming, 773

Hard palate, in cats, pemphigus vulgaris of, 875

Head, feline, nodular/ulcerative dermatoses of, 929

pruritus of, differential diagnosis of, 925–928

skin disorders of, 923–933

Head injury, and alterations to intracranial pressure, effect on anesthetic management, 1074–1075, 1086

anesthesia in, 1086

Head/neck, canine, lymph nodes of, 149–150

lymphocenters of, 155

surgery on, in oncology patient, infection with, 82

Heat, application of, in trauma, 1027

Heinz body formation, in diabetes mellitus, 629

Hemangiosarcoma, adjunct radiation therapy for, 143

hepatic, 326

metastatic, 421

radiographic appearance of, 426
liver, 423
treatment and prognosis in, 431
Hematemesis, in feline idiopathic hepatic lipidosis, 365
Hematologic abnormalities, cancer treatment and, 1404
in liver cancer, 428
in liver disease, 266
paraneoplastic, perioperative management of, 46-51
disseminated intravascular coagulation, 49-50
hyperhistaminemia, 50-51
thrombocytopenia, 46-49
Hematologic complications, of diabetes mellitus, 625-637
treatment of, 632-634
erthrocytes, 627-631
Heinz body formation, 629
hemoglobin glycosylation and oxidation, 627-629
fibrinolysis, 632-634
general mechanisms of, 626-627
ketoadidosis, 626-627
oxidative damage, 626
protein glycosylation, 626
leukocytes, 632
platelets, 632-633
Hematologic syndromes, neoplastic conditions associated with, 1404
Hematoma(s), hepatic, 325
of pinnae, in cats, 935
Hematopoietic growth factors, 1441-1455
erthropoietin, 1442-1444
future use of, for cancer patients, 1412-1413
granulocyte colony-stimulating factor, 1444-1449
granulocyte-macrophage colony-stimulating factor, 1449-1451
interleukin-1, 1452-1453
interleukin-3, 1451
macrophage colony-stimulating factor, 1452
pIXY 321, 1452
stem-cell factor, 1453
Hemodilution, normovolemic, critical need for red blood cells in, 1374
Hemoglobin, acellular, compromise of immune defenses by, 1432
current status of, 1434
efficacy of, 1429-1430
metabolism and toxicity of, 1430-1433
modifications of, 1426-1429
colloid osmotic pressure, 1426-1427
oxygen affinity and, 1426
plasma retention time, 1427
rheology, 1427
sources of, 1429
glycosylation and oxidation of, in diabetes mellitus, 627-629
oxygen capacity of, 1434
solutions of, as blood substitutes, 1418
structure and function of, 1422-1425
Hemolysis, as autotransfusion complication, 1297
with canine blood transfusion, 1350
pathophysiology of, 1336-1339
with feline blood transfusion, 1317-1320
Hemophilia, transfusion for, 1395-1397
Hemorrhage, and anesthesia drugs, in trauma patient, 1088
classification of, 1366
in acute liver failure, management of, 454-455
Hemorrhagic abdominal emergency, as oncologic surgical emergency, 211-213
clinical presentation and diagnosis of, 211-212
pathophysiology of, 211
surgical therapy and aftercare of, 212-213
Hemorrhagic shock, critical need for red blood cells in, 1366-1367
Hemosiderosis, with canine blood transfusion, 1357
Hemostasis, in liver disease, 265
in resuscitation from hemorrhage, 1369
critical need for red blood cells in, 1373
Hemostatic disorders, 1387-1402
blood component administration for, 1282-1283
conditions causing, 1387
thrombocytopenia, 1388-1390
Hemostatic system activation, in canine acute hemolytic transfusion reaction, 1338-1339
Hemothorax, with thoracic trauma, 1033-1034
Hepatic arteriovenous malformations, imaging of, 314
Hepatic aspiration, 275-291
Hepatic coma, 351-352
Hepatic conjugation, tests of, 261-264
Hepatic disease, diffuse, 322-325
focal, 325-327
Hepatic encephalopathy, 337-355
aminos acid metabolism and, 340-341
clinical findings in, 337-338
endogenous benzodiazepines in, 341-343
gamma-aminobutyric acid in, 341
glutamate in, 341
grading system for, 339
in acute liver failure, management of, 452-454
in liver disease, recommendations for, 496-497
in portal hypertension, 466
treatment of, 475
Hepatic encephalopathy (Continued)
pathogenesis of, 338–343
predisposing causes of, 343–345
role of ammonia in, 339–340
therapy of, 343–351
antibiotic, 345–347
diet, 348–351
Hepatic enzyme elevations, with glipizide, 608
Hepatic lipidosis, 324
feline, 295
and acute liver failure, 441
idiopathic, 357–373
clinical findings in, 358–359
comparative aspects of, 357–358
diagnostic imaging of, 497
laboratory findings in, 359–362
lipoprotein abnormalities in, 368–369
pathophysiology of, 366–371
therapy for, 362–366
dietary, 362–364
drug, 365
types of, 358
process of, 299
Hepatic neoplasia, in dog and cat, 419–435.
See also under Liver.
Hepatic/pancreatic complications, with
long-term diabetes mellitus, 739–742
Hepatitis, acidophil cell, canine, 390
and acute liver failure, 441
chronic, active, 388
autoimmune, 392–393
in dogs, 393
leptospirosis-associated, 389
lobular, 387–388
progressive, 387
copper-associated, 390–391
lesions of, 299
lobular-dissecting, 393
long-term, 387–398
active, 300
breed-associated, 391–392
diagnosis of, 394
drug-associated, 390
etiology of, 388–389
infectious canine hepatitis virus–associated, 389
management of, 394–396
Hepatobiliary disease, bile acids in, 503–517
Hepatocellular carcinoma, classification of, 421
gross appearance of, 422
radiographic appearance of, 426–427
treatment and prognosis in, 430–432
Hepatocellular damage, and
hyperbilirubinemia, 261
Hepatolenticular disease, copper
metabolism in, 402
Hematoma(s), 301–302
in dog, 309
Hepatomegaly, generalized, canine, 308
in biliary cirrhosis, 381
with multiple mineralizations, 311
Hepatopathies, copper-associated, 399–417
breed variation in, 411–414
Bedlington terriers, 411–412
Doberman pinschers, 413–414
Skye terriers, 413
West Highland white terriers, 412–413
clinical picture of, 403–404
diagnosis of, 404–405
emergency treatment of, 411
guidelines for therapy, 414–415
treatment of, 405–411
Hepatotoxicity, copper-associated, 399
Hepatotoxins, and acute liver failure, 438–440
Hexose-monophosphate shunt, in red
cell metabolism, 1265
Hormonal agents, effects on wound
healing, 116–117
Hormone-sensitive lipase system,
activation of, in diabetes mellitus, 564
Host-tumor cell interactions, in tumor
metastasis, 233–234
Humerus, high-velocity gunshot injury of,
treatment of, 1123
Hyaluronate, for penetrating joint injuries,
1208
Hydrotherapy, in spinal fracture/luxation,
1169–1170
in trauma, 1028
Hyperadrenocorticism, canine, insulin
resistance vs, 699–701
transfusion for, 1399
feline, insulin resistance vs, 701–702
in cats, and excessive shedding of whole
hairs, 862
cutaneous manifestations of, 951–953
differential diagnosis of, 880
Hyperammonemia, in liver disease,
recommendations for, 496
in portal hypertension, 470
with canine blood transfusion, 1355
Hyperbaric oxygen treatment, for spinal
cord ischemia, 1151
Hyperbilirubinemia, tests of, 261
Hypercalcemia, as paraneoplastic
syndrome, perioperative management
of, 51–53
with liver cancer, 428–429
Hypercatecholaminemia, as paraneoplastic
syndrome, perioperative management
of, 56
Hypercortisolism, in cats, cutaneous
manifestations of, 955
Hyperhistaminemia, as paraneoplastic
syndrome, perioperative management
of, 50–51
Hyperinsulinemia, in non-insulin-dependent diabetes mellitus, 557
Hyperlipidemia, and canine insulin resistance, management of, 706
insulin resistance vs, 704
with diabetes mellitus, dietary recommendations for, 594
Hypernatremia, in acute liver failure, management of, 452
Hyperosmolar coma, in diabetes mellitus, 567
Hyperosmolarity, with diabetic ketoacidosis, 619-620
Hypertension, portal, diagnosis of, 331
with diabetes mellitus, dietary recommendations for, 595
with hemoglobin solutions, 1431
Hypematemesis, in acute liver failure, management of, 452
Hyperosmolar coma, in diabetes mellitus, 567
Hyperosmolarity, with diabetic ketoacidosis, 619-620
Hypertension, portal, diagnosis of, 331
with diabetes mellitus, dietary recommendations for, 595
with hemoglobin solutions, 1431
Hyperthyroidism, and feline insulin resistance, management of, 705
feline, case study of, 266-267
insulin resistance vs, 702-703
in cats, cutaneous manifestations of, 950-951
Hyperventilation, for cerebral edema, 352
Hypoaalbuminemia, in cancer patient, blood components for, 1410
in liver disease, 264
Hypoallergenic diets, for feline dermatoses, 999
Hypofibrinogenemia, transfusion for, 1394-1395
Hypoglycemia, as paraneoplastic syndrome, perioperative management of, 53-56
in liver disease, 264
with diabetic ketoacidosis, 620-621
with glipizide, 608
with insulin, emergency therapy of, 640-641
with liver cancer, 428
Hypokalemia, in acute liver failure, management of, 451
with diabetic ketoacidosis, 621-622
correction of, 642-644
Hypophosphatemia, with diabetic ketoacidosis, 622-623
correction of, 644
Hypoprothrombinemia, blood component administration for, 1283
in liver disease, 264
Hypoesthesia, for feline atopy, 856
for feline dermatoses, 999
Hypothermia, with canine blood transfusion, 1355
Hypothyroidism, canine, and insulin resistance, management of, 706, 708
insulin resistance vs, 703
feline, and excessive shedding of whole hairs, 862
cutaneous manifestations of, 951
Hypotrichosis, hereditary, in cats, 852
Hypovolemia, blood component administration for, 1283
with thoracic trauma, 1042
Iatrogenic mandibular fracture, 1144-1145
Idoxuridine, for feline dermatoses, 989-990
Illness, concurrent, with diabetes mellitus, insulin resistance vs, 696-697
Immobilization, in gunshot injuries, 1119
Immune compromise, by acellular hemoglobin, 1432
in cancer catabolism, 64-65
Immune response, regional lymph node in, 157
Immune-mediated thrombocytopenia, transfusion for, 1389-1390
Immunofluorescence/immunohistochemical staining, in feline dermatology, 791
Immunomodulating drugs, for feline dermatoses, 994
Immunomodulation, by ursodeoxycholate, 512
Immunosuppression, with canine blood transfusion, 1349-1350
Immunosuppressive agents, for feline dermatoses, 994-996
Immunotherapy, for feline dermatoses, 999
Impression smears, for yeast, in feline dermatology, 784-785
from ulcerative lesions, in cats, 871
Incisions, types of, in surgical oncology, 100
Indolent ulcer, in cats, 845-848
diagnosis of, 847
of lip, 931
therapeutic management of, 847-848
Infection(s), and hepatic encephalopathy, 344
and insulin resistance, management of, 705-706
control of, in surgery, in diabetes mellitus, 659
in surgical oncology patient, 75-94
antibiotic drugs for, 78
catabolism in, 64-65
clinical significance of, 77-79
incidence of, 77
pathophysiology of, 75-77
pharmacokinetics in, 79-80
prophylactic antibiotics for, 79-81
risk factors for, 77, 79
specific guidelines in, 81-83
abdominal surgery, 82-83
head and neck surgery, 82
neurosurgery, 82
orthopedic surgery, 81
Infection(s) (Continued)

thoracic surgery, 82
therapeutic drugs for, 81

treatment principles for, 79–81
with diabetes mellitus, 618
insulin resistance vs, 696
with long-term diabetes mellitus, 742–746
pathogenesis of, 742–744
respiratory, 745–746
skin, 746
urinary tract, 744–745

Infectious agents, and acute liver failure, 439–441

Infectious canine hepatitis virus, and long-term hepatitis, 389

Infectious dermatoses, in cats, 820–823
dermatophytosis, 822–823
pyoderma/bacterial folliculitis, 820–821

Infectious diseases, in cats, cutaneous manifestations of, 945–950

Infectious thrombocytopenia, transfusion for, 1389

Inflammatory disease, chronic, anemia in, 203
blood components for, 1404–1406

Inhalation anesthetics, for surgical oncology patient, 87

Insect growth regulators, for fleas, in cats, 805–806

Insulin, basal levels of, in normal vs diabetic cats, 540
centralization of, in glucose tolerance test, in cats, 530
dosage of, 681–683
adjustments to, 685–686
by owner, 756–757
for diabetic ketoacidosis, 644–646
for feline diabetes mellitus, 543
formulations of, 677–680
concentration, 680
duration, 679–680
sources, 677–679
frequency of dosing, 683–685
injection location for, 687–688
injection technique for, 687–688, 753–754
mixtures of, 686–687
overdose of, emergency therapy of, 640–641
poor absorption of, insulin resistance vs, 694–695
management of, 705–706
preferred type, for insulin-dependent diabetes mellitus, 753–754
preparations of, 678
characteristics of, 576
regimens of, in dogs and cats, 684, 688.
See also Insulin therapy,
secretion of, amylin inhibition of, 538
impaired, in non-insulin-dependent diabetes mellitus, 529–532, 556
syringes and delivery devices for, 680–682

Insulin resistance, amylin production and, 538
diagnosis and management of, 691–713
differential diagnosis of, 694–704
flow chart for evaluation of, 692
identification of, 758
immunologic, 695–696
management of, 705–706
in non-insulin-dependent diabetes mellitus, 532, 556
initial evaluation of, 692–694
diet and feeding schedule, 693
injection method, 693
insulin underdosage, 693
insulin administration in, guidelines for, 709
management of, 704–710
severe, genetic syndromes of, 704
Insulin secretagogue testing, in feline diabetes mellitus diagnosis, 603–605

Insulin therapy, 677–689
adjustments in, 575–578
dosage, 576
frequency of administration, 578
type of insulin, 576–578
goals of, 756
guidelines for, 709

Insulinoma, perioperative management of, 54–55

Interdental acrylic, for mandibular fracture fixation, 1137, 1139
Interferon-α, for feline dermatoses, 989–990

Interfragmentary wire fixation, of mandibular fracture, 1143–1144

Interleukin-1, as hematopoietic growth factor, 1452–1453

Interleukin-3, as hematopoietic growth factor, 1451

Intermedullary pinning, for mandibular fracture, 1144

Internal fixation, for spinal fracture/luxation stabilization, 1162–1168
cross pins, 1162–1163
dorsal spinal plating, 1166–1167
pins and polymethylmethacrylate, 1163–1165
pins and wires, 1163
skeletal fixation, 1166

Internal hemorrhage, effect on anesthetic management, 1076

Intestinal disorders, with long-term diabetes mellitus, 736–738

Intestinal endoscopy, oncologic applications of, 172–174

Intestinal neoplasm, as oncologic surgical emergency, 217

Intestinal perforation, as oncologic surgical emergency, 217
Intra-abdominal lesions, effect on anesthetic management, 1076
Intradermal skin test, in feline dermatology, 791–793
Intraoperative biopsy, with microscopy, 39–41
Intraoral splints, for mandibular fracture fixation, 1142–1143
Irritant contact dermatitis, in cats, differential diagnosis of, 878
Ischemia, massive, and acute liver failure, 441
Ischioiarial pinning, for coxofemoral joint reduction, 1180–1182
Isoerythrolysis, neonatal, canine blood groups in, 1330
Jet injectors, for insulin, 681
Joint(s), penetrating injuries of, 1197–1223
Keratosis, actinic, in cats, 828–830, 962 of pinnae, 934–935
Ketamine with benzodiazepine, for crash-type anesthesia induction, in trauma patient, 1080
Ketoacidosis, and insulin resistance, management of, 705–706 in diabetes mellitus, 626–627 insulin resistance vs, 696–697
Kidney(s), enlarged, in diabetic nephropathy, 722 ultrasound scan of, 320
Kirschner wire, for coxofemoral joint reduction, 1185
Kitten, radius/ulna fracture in, 1056
L-forms, bacterial, cutaneous, in cats, 893
Labrador retriever, chronic active hepatitis in, 392
Lactulose, for hepatic encephalopathy, 346–348 in acute liver failure, 453
Laparotomy, exploratory, in acute liver failure, 448
Large intestinal surgery, in oncology patient, infection with, 82–83
Larynx, endoscopy of, oncologic applications of, 175
Leiomyosarcoma, hepatic, metastatic, radiographic appearance of, 427
Leishmania, in cats, cutaneous manifestations of, 950
Lens, diabetic cataracts of, extracapsular extraction of, 670–671 protein glycosylation in, 665 metabolic pathways in, in diabetes mellitus, 662–663
Leptospirosis, and chronic active hepatitis, 389
Leukocyte(s), abnormalities of, in diabetes mellitus, 632 characteristics of, 1278–1279
Leukocyte-platelet sensitivity transfusion reaction, canine, 1346–1348 definition and pathophysiology of, 1346–1347 monitoring and documentation of, 1347 prevention of, 1348 treatment of, 1347–1348
Leukocytosis, in liver disease, 266

traumatic luxations of, 1175–1196
coxofemoral, 1176–1186. See also Coxofemoral joint.
general anesthesia for, 1176
Leukocytosis (Continued)
neutrophilic, with liver cancer, 428
Leukopenia, blood components for, 1283
in cancer patient, 1410
Levamisole, for feline dermatoses, 994
LeVeen shunt, for ascites, in portal
hypertension, 479
Limb(s), lymphocenters of, 156
Limb mass, diagnostic imaging of,
algorithm for, 190
Lincosamides, for feline dermatoses,
983–984
Lip(s), of cat, collagenolytic granuloma of,
931–932
indolent ulcer of, 931
pemphigus vulgaris of, 875
Lipid(s), metabolism of, derangements in,
in hyperglycemia, 717
in liver disease, 486–487
Lipidosis, hepatic, feline, idiopathic,
357–373. See also
Hepatic lipidosis.
Lipstick, removal of, in feline grooming,
777
Liquid enteral formula, for cancer patient,
71
Liver, aspiration of, 275–291
biochemical tests of, categories of, 257
biopsy of, 275–291
exploratory celiotomy and, 285–289
biopsy punch technique, 287
excisional biopsy via lobectomy,
288–289
ligature techniques, 286–287
perioperative considerations, 286
wedge resection or partial lobectomy
technique, 287–288
handling of sample, 290
in biliary cirrhosis, 381–382
in feline idiopathic hepatic lipidosis,
361–362
in nonsuppurative cholangitis/cholan-
giohepatitis, 379–380
in portal hypertension, 471
in suppurative cholangitis/cholangio-
hepatitis, 376
indications for, 275
interpretation of, 293–303
laparoscopic, 285
postbiopsy care in, 289–290
prebiopsy considerations in, 276–277
liver size, 277
patient’s physical status, 276
risk for hemorrhage, 276
risk for impaired wound healing,
277
specialty needles for, cost of, 282
specimen from, 293–294
techniques of, 278–289
blind, 278
depressed, 278
elevated, 278
fine-needle, 278
hepatic aspirate, 278
keyhole, 279–281
needle, 279–281
percutaneous, 278
ultrasound-guided, 281–285
transjugular, 289
transthoracic, 285
carcinoids of, 423
centrilobular necrosis and hemorrhage
in, 297–298
circulation of, 461–464
anatomy and physiology, 461–462
pathophysiology, 462–464
cirrhosis of, 300–301
ultrasound scan of, 323
clinicopathologic evaluation of, 257–273
case studies in, 266–271
cholestatic enzymes, 259–260
hepatocellular enzymes, 258–259
degenerative or metabolic changes in,
298–299
diagnostic imaging of, 194–196
disease of. See Liver disease.
eventration into thoracic cavity, 312
failure of, 437–460. See also Liver failure.
fibrosis of, 300–301
fine-needle biopsy of, 34
hepatomas of, 301–302
hyperplastic nodules of, 325
radiographic appearance of, 426
imaging of, 305–335
cholecystography, 315–317
radiographic, 305–307
normal anatomy, 306
size, shape, and margination, 306–
307
with radiographic contrast, 312–315
peritoneography, 313
portography, 313–314
with radiology and ultrasound, 305–
335
with ultrasonography, 317–327
islet cell carcinoma of, gross appearance
of, 422
lesions of, diagnostic expectations in,
296–298
inflammatory, 299–300
location and categorization of, 294–296
zonal, 296
lobectomy of, with surgical stapler, 288
necrosis of, canine, case study of, 269
causes of, 300
neoplasia of, 419–435
adjuvant chemotherapy for, 432
biopsy procedures for, 429–430
breed, age, and sexual predilections
in, 421
etiology of, 424
gross distribution of, 423
incidence and prevalence of, 419
laboratory findings in, 428–429
laparoscopy of, 178
metastatic, 327
pathology of, 421–424
presenting signs and findings in, 424–425
primary, 326
radiographic and ultrasonographic findings in, 425–428
scintigram of, 195
surgery for, 429–430
treatment and prognosis in, 430–432
tumor types in, 419–421
position of, changes in, 312
radiopacity of, alterations in, 307–311
regeneration of, 301–302
secretion of, tests of, 261–264
small, in dog, 310
surgery of, in oncology patient, infection with, 83
synthesis by, tests of, 264–266
ultrasound anatomy of, 319–322
uptake by, tests of, 261–264
vasculature of, abnormalities of, 331–333
venous congestion of, 331
Liver disease, diagnosis of, bile acids in, 505–507
dietary recommendations for, 491–496
diffuse, 322–325
homemade diets for, 495
in cats, drugs for, 378
laboratory data in, evaluation of, 271
metabolite detoxification and excretion in, 490–491
nutritional management of, 485–501
transfusion for, 1398
with long-term diabetes mellitus, 739–740
Liver enzymes, in liver cancer, 429
Liver failure, acute, 437–460
clinicopathologic findings in, 443–445
coagulation studies in, 444–445
diagnosis of, 442–448
ancillary testing in, 446–447
histopathologic, 447–448
etiology of, 438–441
fluid therapy for, 451
general therapy for, 452–455
hepatotoxins and, 438–440
history in, 442
imaging techniques for, 445–446
liver function testing in, 445
major organ system support in, 449–451
management of, 448–456
nursing care for, 456
nutritional support for, 455–456
physical examination in, 442–443
urinalysis in, 444–445
fulminant, 351–352
Liver function, and anesthesia drugs, in trauma patient, 1088–1089
testing of, in acute liver failure, 445
in feline idiopathic hepatic lipidosis, 360
Lobular fibrosis, peripheral, 294
Local analgesia, in trauma patient, 1083–1084
Lumbar spine, fracture of, 1157
osteomyelitis following, 1171
skeletal fixation for, 1164–1165
Lung, endoscopy of, oncologic applications of, 175–176
fine-needle biopsy of, 35
Lupus erythematosus, in cats, differential diagnosis of, 876
Lymph node(s), canine, 148–150
abdominal viscera, 153–154
head and neck, 149–150
thoracic, 151–152
internal structure of, 159
metastases to, and systemic dissemination, 161
common tumors causing, 162
definition of, 159
survival time with, 160
regional, anatomy of, 147–150
clinical management of, 147–165
abnormal, 162–163
goals and strategies, 159–161
normal, 161–162
surgical courses of action, 161–163
metastases to, pathophysiology of, 154–159
physiology of, 150–159
tumor metastases to, 234
Lymphangiomata, dermal/subcutaneous, in cats, 973
Lymphangiosarcomas, dermal/subcutaneous, in cats, 973
Lymphocenters, of abdomen, 158
of head/neck, 155
of limbs, 156
of thorax, 157
of torso, 156
Lymphoma, diagnostic imaging of, 198–200
feline, cutaneous/subcutaneous, 971–973
epitheliotrophic, differential diagnosis of, 881–882
hepatic, 420
radiographic appearance of, 426
Lymphosarcoma, feline, 295
gastric, endoscopy of, 170
hepatic, 323–324
intestinal, endoscopy of, 173
Lynxacarus radovskyi, in cats, 824–825
Macrolides, for feline dermatoses, 983
Macronutrient content, for diabetes mellitus, 588–593
- carbohydrate, 589–590
- fat, 589
- fiber, 590–592
- protein, 589

Macrophage colony-stimulating factor, as hematopoietic growth factor, 1452

Magnetic resonance imaging, as diagnostic imaging modality, 186–187

Malignancy, dissemination of, with autotransfusion, 1299–1300

Mammary masses, diagnostic imaging of, 193

Mandibular fracture(s), 1127–1148
- anatomy of, 1131–1132
- antimicrobial therapy for, 1132
- biomechanics in, 1132
- caudal (distal), 1145–1146
- external skeletal fixation for, 1138–1142
- fixation techniques for, 1134–1135
- general anesthesia in, 1129
- iatrogenic, 1144–1145
- interdental fixation for, 1135–1138
- interfragmentary wire fixation of, 1143–1144
- intermedullary pinning of, 1144
- intraoral splints for, 1142–1143
- patient assessment in, 1128
- perifracture tooth pathology in, 1133–1134
- pharyngotomotomy intubation in, 1130
- repair of, procedures for, 1131
- skull fractures with, 1130–1131
- symphyseal, repair of, 1143
- temporomandibular joint luxation, 1146
- tracheostomy in, 1128–1129
- tube alimentation in, 1130
- Mannitol, for cerebral edema, 352
- Manometry, in portal hypertension, 473
- Mast cell tumor(s), adjunct radiation therapy for, 142–143
- cutaneous, in cats, 969–971
- Mechanical compression, effect on anesthetic management, 1076
- Mechanical hemolysis, with canine blood transfusion, 1350
- Mediastinal injury, with thoracic trauma, 1039–1040
- Medroxyprogesterone acetate, for feline dermatoses, 993
- Megestrol acetate, for feline dermatoses, 992–993
- Melanoma, electrofulguration of, 101
- spectrum of clinical potential in, 18
- Melena, in feline idiopathic hepatic lipidosis, 365
- Mesenchymal tumors, cutaneous/subcutaneous, in cats, 966–974
- Metabolic disease, and acute liver failure, 441
- Metastatic cascade, 231–233
- Methionine, avoidance of, in liver disease, 496
- Methylprednisolone sodium succinate, for spinal cord ischemia, 1151
- Metronidazole, for feline dermatoses, 985
- for hepatic encephalopathy, 347
- Microalbuminuria, in diabetic nephropathy, 722–723
- Microaneurysms, in canine diabetic retinopathy, 719
- Microemboli, dissemination of, with autotransfusion, 1300
- pulmonary, with canine blood transfusion, 1355–1356
- Micrometastatic disease, implications of, 235
- Micronutrients, for diabetes mellitus, 593
- in liver disease, metabolism of, 489–490
- requirement for, 493–494
- Microsporum canis, and feline dermatophytosis, 901
- vaccine for, 918
- Minerals, in hepatic encephalopathy, 350–351
- Mitoxantrone treatment, neutrophil counts in, effect of granulocyte colony-stimulating factor on, 1448
- Monopty instrument, for liver biopsy, 284
- Morphine, for chronic pain, in surgical oncology patient, 91
- Mosquito-bite hypersensitivity, in cats, 838–840
- Mouth, plasma cell pododermatitis of, in cats, 883
- Mucopolysaccharidosis, in cats, cutaneous manifestations of, 955–956
- Mucosal inflammation, with diabetes mellitus, 733
- Multiple fibrosarcomas, of young cats, 966–967
- Mupirocin, for feline dermatoses, 985
- Muzzle coaptation, temporary, for mandibular fracture, 1134
- Mycobacterial infections, cutaneous, in cats, 890–892
- Myelin, nonenzymatic glycosylation of, with long-term diabetes mellitus, 726
- Myelolipoma, liver, 423
- Nail(s), in feline grooming, 777–778
- Nail clippers, for feline grooming, 771–772
- Nail polish, removal of, in feline grooming, 777
- Nailbed tumors, in cats, 973–974
- Naloxone, for feline dermatoses, 991
- Narcotic antagonists, for feline psychogenic alopecia, 861
Nasal cavity, diagnostic imaging of, 189
Nasoesophageal feeding tube, selection and use of, 70
Neck, pruritus of, in cats, differential diagnosis of, 926–928
Neoadjuvant chemotherapy, 133
Neomycin, for hepatic encephalopathy, 345–347
Neoplasms, in cats, cutaneous/subcutaneous, 897, 961–979
Neoplastic disease, and acute liver failure, 441
Nephrotic syndrome, transfusion for, 1398
Nerve damage, with gunshot injuries, 1117
Neuroleptanalgesia, for trauma patient, 1078–1079
Neurologic system, support of, in acute liver failure, 450–451
Neuromuscular blocking agents, for anesthesia maintenance, in trauma patient, 1082
Neurosurgery, in oncology patient, infection with, 82
Neutropenia, as paraneoplastic syndrome, perioperative management of, 48
treatment of, with granulocyte colony-stimulating factor, 1449
with granulocyte-macrophage colony-stimulating factor, 1451
Neutrophil counts, effect of granulocyte colony-stimulating factor on, 1445–1447
Nocardial abscesses, cutaneous, in cats, 889
Nodules, in cats, 887–899
Nonketotic hyperosmolar coma, diabetic, emergency therapy of, 646–648
Nonsteroidal anti-inflammatory drugs, for analgesia, in trauma patient, 1083
for penetrating joint injuries, 1208
Nonunion, in open fracture, management of, 1107
Nose, endoscopy of, oncologic applications of, 176–178
of cat, dermatoses of, 924
eosinophilic dermatitis of, 933
Notoedric mange, in cats, 823
NSAIDs, for chronic pain, in surgical oncology patient, 90
Nuclear medicine, as diagnostic imaging modality, 186
Null hypothesis, in oncology study, 7
Nursing care, for acute liver failure, 455–456
general, in trauma, 1024–1025
Nutrition, in acute liver failure, 455–456
in liver disease, 485–501
Nutritional disorders, in cats, and excessive shedding of whole hairs, 866
Nutritional status, and wound healing, 113
assessment of, perioperative, 66
effect of tumors on, 62–71
anorexia and cachexia, 62–64
consequences of catabolism, 64–65
fluid and food selection, 69–71
providing perioperative nutritional support, 65–69
refeeding in, 64
Nutritional support, perioperative, in cancer, 61–74
Nutritional therapy, for diabetes mellitus, 585–597
caloric intake, 586–587
feeding schedule, 587–588
food form, 588
macronutrient content, 588–593
Obesity, amylin and, 541
and feline diabetes mellitus, 532–533, 601
and insulin resistance, 697
management of, 705–706
Observational studies, in oncology, 12
Ocular manifestations, of canine diabetes mellitus, 661–676. See also Diabetic cataracts.
Oncologic applications, of diagnostic imaging techniques, 183–203. See also Diagnostic imaging.
of endoscopy, 167–181. See also Endoscopy.
Oncology, epidemiology of, 1–15
surgical, principles of, 95–108. See also Surgical oncology.
surgical emergencies in, 205–221
algorithm for, 207
gastroenterologic, 215–218
hemorrhagic abdominal, 211–213
pericardial effusion/cardiac tamponade, 206–209
respiratory, 209–211
urogenital, 213–215
Oncology literature, how to read, 1–15
Oncology study, analysis and sample size of, 7
assignment of exposure/intervention in, 4–6
confounding variables in, 10–14
design and characteristics of, 4
effect or relationship in, strength and precision of, 9–10
findings in, importance of, 14–15
hypotheses in, 7
initial screening criteria for, 2–3
interpretation and extrapolation in, 10–11
objectives of, achievement of, 14–15
assessment of, 3
Oncology study (Continued)
outcome of, assessment of, 6-7
populations used in, 3-4
selection bias in, 5
statistical significance testing in, 7-9
study design in, 11-14
case-control, 13
cohort, 13
cross-sectional, 12-13
descriptive, 11
experimental, 14
exploratory, 11-12
observational, 12
validity of, assessment criteria for, 3-7
variables in, 5
Open fracture, classification of, 1093-1095
fixation of, 1101-1104
management of, 1093-1110
complications of, 1105-1108
amputation, 1107-1108
delayed union/nonunion, 1107
osteomyelitis, 1106-1107
wound infection, 1105-1106
for referral, 1095-1096
limb management in, 1099-1105
bone grafts, 1104
fracture fixation, 1101-1104
postoperative, 1105
soft tissue debridement, 1100
soft tissue grafts, 1104-1105
wound lavage, 1100-1101
patient management in, 1096-1099
bacterial cultures and antibiotics, 1098
initial assessment, 1096-1098
initial wound care, 1098
Open incisional biopsy, 39
Opioid analgesics, for trauma patient, 1078-1079
potency and classification of, 1078
Oral cavity, diagnostic imaging of, 189
Oral diseases, with long-term diabetes mellitus, 732-735
Oral hypoglycemics, for feline diabetes mellitus, 606-610
Glipizide, 607. See also Glipizide.
indications for, 606
mechanisms of action of, 606-607
second-generation sulfonylureas, 607
Organophosphates, for fleas, in cats, 803-804
Orthopedic emergencies, animal abuse in, 1055-1058
client counseling in, 1047-1058
communication and support, 1048-1049
consent for treatment, 1050
crisis, 1048
discharge planning, 1052-1053
economics, 1051-1052
P value, calculation of, in oncology study, 8
Pain, in surgical oncology patient, 75-94
analgesics for, 87
pathophysiology and clinical significance of, 84-85
postamputation, 89
recognition of, 85-86
specific guidelines for, 86-89
therapy for, 90-92
treatment principles for, 86
types of, 83-84
relief of, in spinal fracture/luxation, 1169
Paint, removal of, in feline grooming, 776
Palliation, in surgical oncology, 96
Pancreas, diagnostic imaging of, 194-196
histopathology of, in feline diabetes mellitus, 602
Pancreatic disease, in cats, cutaneous manifestations of, 955
with long-term diabetes mellitus, 740-741
Pancreatic insufficiency, exocrine, with diabetes mellitus, dietary recommendations for, 594
Pancreatic islets, amyloid in, age of cat and, 535
and feline diabetes mellitus, 534
Pancreatitis, acute, in diabetes mellitus, surgery in, 657
transfusion for, 1399
chronic, with diabetes mellitus, 733, 741
in diabetes mellitus, dietary recommendations for, 594
treatment of, 741–742
Pancytopenia, as paraneoplastic syndrome, perioperative management of, 48
Pansteatitis, in cats, cutaneous manifestations of, 956
Paracentesis, for acute liver failure, 446
in portal hypertension, 471
for ascites, 478
Paraneoplastic syndromes, 45–60
common, 46–47
definition of, 45
in liver neoplasia, 425
perioperative management of, hematologic abnormalities, 46–51
hypercalcemia, 51–53
hypercatecholaminemia, 56
hypoglycemia, 53–56
pheochromocytoma, 56
thyrotoxicosis, 56–57
Paraparesis, symmetric, with canine diabetic neuropathy, 724
Parasitic dermatoses, in cats, 823–825
Parasitic infections, and acute liver failure, 440
Parasitic infestations, feline, of face, 926
of pinnae, 935
Parasiticides, for feline dermatoses, 987–988
Parenteral feeding, perioperative, 68–69
Patent ductus venosus, imaging of, 315
Patient assessment, in blood component transfusion, 1284–1287
Pelvis, soft tissue sarcoma of, magnetic resonance imaging of, 190
Pemphigus, feline, differential diagnosis of, 873–876
pemphigus erythematosus, 828
pemphigus foliaceus, 825–828
Pen injectors, for insulin, 681
Penetrating joint injuries, management of, 1197–1223. See also Joint(s).
Penicillamine, for copper-associated hepatopathies, 408–409
Penicillins, for feline dermatoses, 981–982
Pennyroyal oil, for fleas, in cats, 806
Perfluorocarbons, oxygen capacity of, 1433
Perfluorochemicals, as oxygen substitutes, 1433–1434
Pericardial effusions, as oncologic surgical emergency, 206–209
clinical presentation and diagnosis of, 208
pathophysiology of, 206–208
surgical therapy and aftercare of, 208–209
Pericholangitis, lesions of, 299
Periodontal disease, and iatrogenic fracture, 1144–1145
with long-term diabetes mellitus, 732
Peritoneovenous shunt, for ascites, in portal hypertension, 478
Peritonitis, as oncologic surgical emergency, 217
Pesticides, for fleas, in cats, 801–811
borates, 804
insect growth regulators, 805–806
organophosphates, 803–804
pyrethrin/pyrethroid insecticides, 804–805
Phacoemulsification, for canine diabetic cataracts, 669–670
Phaeohyphomycoses, cutaneous, in cats, 895–896
Pharmacologic management, of pain and infection, in surgical oncology patient, 75–94
Pharyngotomy intubation, in mandibular fracture, 1130
Phenobarbital, for feline dermatoses, 990
Phenothiazines, for trauma patient, 1077
Pheochromocytoma, as paraneoplastic syndrome, perioperative management of, 56
Phycomycosis, intestinal, with secondary liver disease, 270–271
Physical examination, in open fracture management, 1097
in trauma, 1015–1018
Physical restraint, for feline psychogenic alopecia, 861
Physical therapy, in spinal fracture/luxation, 1170
in trauma patient, 1025–1028
Pili torti, in cats, 852
Pinnae, in cats, cutaneous disorders of, 934–936
pIXY 321, as hematopoietic growth factor, 1452
Plague, in cats, cutaneous manifestations of, 948–949
Plantigrade stance, with feline diabetic neuropathy, 724
Plasma, characteristics of, cryo-poor, 1279
fresh frozen, 1279
platelet-rich, 1278
Plasma extractor, for blood banking, 1255
Plasma products, frozen, quality control in, 1259
storage of, 1257–1258
Plasma retention time, and hemoglobin modifications, 1427
Platelet(s), abnormalities of, in diabetes mellitus, 632–633
Platelet(s) (Continued)
concentration of, characteristics of, 1278
consumption of, transfusion for, 1390.
critical need for, 1374–1383
in disseminated intravascular coagulation, 1378–1383
secondary survey in, 1374–1376
emergency laboratory assessment, 1374–1375
history, 1374
laboratory testing, 1375–1376
physical examination, 1374
therapeutics in, 1376–1378
disorders of, as autotransfusion complication, 1298–1299
functional, transfusion for, 1391–1393
reduction in, as paraneoplastic syndrome, perioperative management of, 46–49
sequestration of, transfusion for, 1390
Platelet products, frozen, quality control in, 1259–1260
storage of, 1258
Platelet storage pool disease, transfusion for, 1391
Platelet-derived growth factor, for impaired wound healing, 121–122
Pneumothorax, with thoracic trauma, 1032–1033
Pododermatitis, in cats, plasma cell, 940
differential diagnosis of, 882–883
Pododermatoses, in cats, 936–940
disorders of claws and ungual folds, 938–940
nodules, draining tracts, ulcers, and abscesses, 937–938
scaling, crusting, pruritic, 937
Polychondritis, relapsing, of pinnae, in cats, 935–936
Polyhydroxydine solution, for feline dermatoses, 1000
Polysulfated glycosaminoglycans, for penetrating joint injuries, 1208
Portal clearance, tests of, 261–264
Portal hypertension, 461–483
consequences of, 466–468
diagnosis of, 468–473
clinical findings, 468–469
evaluation in, 469–473
imaging in, 472–473
laboratory findings, 469–472
diseases causing, 464–465
pathophysiology of, 462–464
prognosis in, 480
treatment of, 473–480
Portal vasculature, intrahepatic, imaging of, 314
Portal vein, ultrasound scan of, 320
Portal venography, in portal hypertension, 472
Portal-azygos shunt, imaging of, 316
Portal-colic shunt, imaging of, 315
Portocaval anastomosis, for ascites, in portal hypertension, 479–480
Portosystemic anastomosis, for ascites, in portal hypertension, 479
Portosystemic shunt, canine, case study of, 267–269
imaging of, with radiographic contrast, 314
ultrasonographic findings in, 332
with portal hypertension, 466
Post-transfusion purpura, with canine blood transfusion, 1348
Potassium, for hepatic encephalopathy, 346
replacement of, in diabetic ketoacidosis, 622, 643
Potassium hydroxide preparations, in feline dermatology, 783–784, 786
Fovirus, in cats, cutaneous manifestations of, 945–946
Premedication, of trauma patient, 1077–1079
Preoperative staging, in surgical oncology, 224
Proctoscopy, rigid, oncologic applications of, 174
Progestogens, for feline dermatoses, 992–993
Prognosis, in orthopedic emergencies, 1049–1051
Proligestone, for feline dermatoses, 993
Propofol, for crash-type anesthesia induction, in trauma patient, 1080
Propanoephene, for chronic pain, in surgical oncology patient, 90–91
Propranolol, for portal hypertension, 474
Protein(s), dietary, in diabetes mellitus, 589
in feline idiopathic hepatic lipidosis, 362–363
in hepatic encephalopathy, 349
glycosylation of, in diabetes mellitus, 626
in hyperglycemia, 717
in liver disease, metabolism of, 487–489
requirement for, 492–493
liver synthesis of, 488
Proteinuria, in diabetic nephropathy, 722
Prothrombin deficiency, transfusion for, 1395
Prothecosis, cutaneous, in cats, 896–897
Protozoal diseases, in cats, cutaneous manifestations of, 875, 950
Pruritus, in cats, and excess hair loss, 852–853
causes of, 853
diagnostic procedures in, 780
of face, 928
of head, differential diagnosis of, 925–928
of neck, differential diagnosis of, 926–928

Pseudorabies, in cats, cutaneous manifestations of, 948

Psychogenic alopecia, in cats, 858–861

Pulmonary injury, with thoracic trauma, 1037–1038

Pulmonary microembolism, with canine blood transfusion, 1355–1356

Punch biopsy, of ulcerative lesion, in cats, 872

Purpura, vascular, transfusion for, 1393–1394

Pustules, in cats, diagnostic procedures in, 780

Pyoderma, in cats, 820–821

Pyometra, surgery in, in diabetes mellitus, 657

Pyrexia, with feline blood transfusion, 1317

Red blood cell(s), abnormalities of, in diabetes mellitus, 629–631

replacement of, calculation of volume for, 1371

in resuscitation from hemorrhage, critical need for red blood cells in, 1370–1371

Regional analgesia, for pain, in surgical oncology patient, 89

Regional lymph node, clinical management of, 147–165. See also Lymph node(s).

Relapsing polychondritis, of pinnae, in cats, 935–936

Renal failure, acute, with canine blood transfusion, 1339–1340

anemia in, erythropoietin for, 1443

Renal function, and anesthesia drugs, in trauma patient, 1089–1090

Renal system, support of, in acute liver failure, 450

Respiratory emergency, as oncologic surgical emergency, 209–211

clinical presentation and diagnosis of, 209–210

pathophysiology of, 209

surgical therapy and aftercare of, 210–211

Respiratory function, and anesthesia drugs, in trauma patient, 1087–1089

compromise of, with thoracic trauma, 1040

Respiratory infections, with long-term diabetes mellitus, 745–746

Respiratory system, support of, in acute liver failure, 449

Restraint, in feline grooming, 768–769

Resuscitation, from hemorrhage, critical need for red blood cells in, 1368–1373

Retinal detachment, following canine cataract removal, 672

Retinal hemorrhages, in canine diabetic retinopathy, 719

Retinoids, for feline dermatoses, 996–998

Rhinoscopy, oncologic applications of, 176–178

Rhodococcus equi infections, cutaneous, in cats, 892

Rib fracture, with thoracic trauma, 1036–1037

Saline solution, for shock, in trauma, 1020

Sanctuary sites, and chemotherapy failure, 136

Saprophytic fungal infections, cutaneous, in cats, 895–896

Sarcoma, soft tissue, adjunct radiation therapy for, 143–144

Scaling, in cats, diagnostic procedures in, 780
Scaling dermatoses, of face, in cats, 924–928
Scintigraphy, in portal hypertension, 472
Scissors, for feline grooming, 771
Scotch tape preparations, in feline dermatology, 782–783
Scraping smears, for yeast, in feline dermatology, 784–785
Seborrhea, in cats, cutaneous manifestations of, 956
Sedation, in feline grooming, 768
Self-trauma, in cats, and excess hair loss, 852–861
atopy, 854–857
cheyletiellosis, 857
dermatophytosis, 857–858
dietary hypersensitivity, 858
flea bite hypersensitivity, 853–854
otocariosis, 857
pruritic vs psychogenic, 852–853
psychogenic alopecia, 858–861
trombiculiasis, 857

differential diagnosis of, 881
Sensory polyneuropathy, with long-term diabetes mellitus, 725
Sepsis, as autotransfusion complication, 1299
with surgery, in diabetes mellitus, 655–656
Septic arthritis, radiographic appearance of, 1204
Serum urea nitrogen, in liver disease, 265
Shampoo, for feline grooming, 771, 773
Shock, development of, with canine blood transfusion, 1339–1340
with gunshot injuries, 1116
with trauma, fluid therapy in, 1020
Sialosis, with long-term diabetes mellitus, 732
Siamese cat, pinnal alopecia of, 936
psychogenic alopecia in, 859
severe idiopathic facial pruritus in, 928
Siberian husky, spinal injury in, 1056
Simultaneous chemotherapy, 134
Skin biopsy, in feline dermatology, 790–791
Skin disease(s), in cats, eosinophilic, 833–850
erusive and ulcerative, 871–885
Skin fragility syndrome, in cats, cutaneous manifestations of, 956
differential diagnosis of, 879
Skin infections, with long-term diabetes mellitus, 746
Skin scrapings, in feline dermatology, 781–782
Skull, osteosarcoma metastasis to, scintigram of, 191
trauma to, and mandibular fractures, 1127–1148. See also Mandibular fracture(s).
Skunk odor, removal of, in feline grooming, 777
Skye terrier, chronic active hepatitis in, 399
copper-associated hepatopathy in, 413
Slicker brush, for feline grooming, 769–770
Small animal(s), blood component administration to, principles of, 1277–1290
Small animal practitioner, blood banking for, 1232–1236
Small intestine, endoscopy of, oncologic applications of, 172–174
infection of, in surgical oncology patient, 82
Soft tissue, debridement of, in open fracture management, 1100
grafts of, for open fracture fixation, 1104–1105
injuries to, with thoracic trauma, 1035–1036
Soft tissue sarcoma, adjunct radiation therapy for, 143–144
Solar dermatitis, in cats, 828–830, 926
Solitary fibrosarcoma, of older cat, 967–968
Somatostatin, for insulinoma, 55
Sorbitol, accumulation of, in hyperglycemia, 716
Sphinx cat, hairlessness of, 852
Spinal cord, diagnostic imaging of, 187–189
ischemia of, medical treatment of, 1151
Spinal fracture/luxation, 1149–1174
classification of, 1155–1158
diagnosis of, 1152–1155
location of injury in, 1154
neurologic examination in, 1153
perioperative considerations in, 1149–1160
emergency evaluation and stabilization, 1149–1150
medical treatment of acute injury, 1150–1152
prognosis in, 1161
radiography of, 1154
spinal compression in, 1160–1161
spinal cord blood flow in, 1150
stabilization of, complications of, 1170–1172
methods of, 1161–1172
biomechanical comparisons of, 1168
external coaptation, 1162
external skeletal fixation, 1162
internal fixation, 1162–1168
postoperative and convalescent care in, 1168–1170
surgical treatment of, nonsurgical vs, 1158–1160
spinal compression in, 1160–1161
Spinal trauma, effect on anesthetic management, 1076
Spironolactone, for ascites, in portal hypertension, 476
Spleen, and anesthesia drugs, in trauma patient, 1088
diagnostic imaging of, 194–196
fine-needle biopsy of, 34
Sporotrichosis, cutaneous, in cats, 894–895
Squamous cell carcinoma, in cats, epithelial, 961–964
of face, 927
of pinnae, 934–935
Staging, preoperative, in surgical oncology, 97–98, 106, 224
Steatorrhea, with long-term diabetes mellitus, 741
Steatosis, with diabetes mellitus, 733, 740
Steinmann’s pin, for coxofemoral joint reduction, 1185
for mandibular fracture fixation, 1139, 1141
Stem-cell factor, as hematopoietic growth factor, 1453
Steroids, and alopecia, in cats, 863
for feline dermatoses, 993–994
Stifle, penetrating injury of, 1199
traumatic luxation of, 1186–1190
complications of, 1190
diagnosis of, 1187
prognosis in, 1190
treatment of, 1187–1190
arthrodesis, 1190
open reduction and internal stabilization, 1187–1189
transarticular pinning, 1189
Stomach, endoscopy of, oncologic applications of, 170–172
Stomatitis, in cats, differential diagnosis of, 882
ulcerative, causes of, 874
Stout’s loop, for interdental mandibular fracture fixation, 1136, 1139
Strength, in observational studies, 12
Streptozotocin, for insulinoma, 55
Stud tail, in feline grooming, 775–776
Subungual tumors, in cats, 973–974
Sulfas, potentiated, for feline dermatoses, 984
Surgery, as cancer therapy, 22–23
primary, critical need for red blood cells in, 1367–1368
Surgical margins, in oncologic surgery, 224
Surgical oncology, 95–108
aftercare in, 105–107
attitudes in, 225
complication management in, 96
emergencies in, 96
future direction of, 227–228
goals in, 95–97
infection in, pharmacological management of, 75–94
past progress in, 225
patient preparation in, 99
planning in, 97–99
present status of, 226–227
science of, 223–228
surgical margins in, 104–106
surgical technique in, 99–104
tissue seeding and wound protection in, 102–103
TNM staging system in, 97–98
treatment of metastases in, 97
wound reconstruction in, 103–104
Suture material, in oncologic surgery, 103
Symphyseal fracture, repair of, 1143
Systemic diseases, in cats, cutaneous manifestations of, 945–959
Talocrural joint, penetrating injury of, 1201
Tapazol administration, in cats, cutaneous manifestations of, 952
Tars, for feline dermatoses, 1000
Taste impairment, with long-term diabetes mellitus, 732
Tear stains, removal of, in feline grooming, 777
Teatree oil, for fleas, in cats, 806
Telogen effluvium, in cats, 1190
of, 1199
Teat, in cats, 875
Thallium toxicity, cutaneous manifestations of, 954–955
Thermal hemolysis, with canine blood transfusion, 1350
Thigh, in cats, eosinophilic granuloma of, 840
Thoracic trauma, 1032–1033
Tetracyclines, for feline dermatoses, 983
2,3,2-Tetramine, for copper-associated hepatopathies, 409–410
Thermocoupling, with copper-associated hepatopathies, 409–410
Therapeutic algorithm, 192
Therapeutic algorithm for, 192
fine-needle biopsy of, 34–35
Thoracic surgery, in oncology patient, infection with, 82
Thoracic trauma, effect on anesthetic management, 1075
fracture-associated, 1031–1046, 1156
cardiac injury, 1038–1039
categories of, 1031
chest wall injuries, 1035–1037
rib fracture, 1036–1037
soft tissue trauma, 1035–1036
mediastinal injury, 1039–1040
pleural space-occupying lesions, 1032–1035
Thoracic trauma (Continued)
  chylothorax, 1034
diaphragmatic hernia, 1034–1035
hemothorax, 1033–1034
pneumothorax, 1032–1033
pulmonary injury, 1037–1038
initial management of, 1040–1043
algorithm for, 1041
Thoracic wall defects, repair of, in oncology patient, 104
Thorax, canine, lymph nodes of, 151–152
diagnostic imaging of, 192–193
examination of, in trauma, 1017–1018
lymphocenters of, 157
Thrombocytopenia(s), as paraneoplastic syndrome, perioperative management of, 46–49
drugs causing, 1377
in cancer patient, blood components for, 1409
transfusion for, 1389
Thrombopathia, transfusion for, 1391, 1393
Thyroid, carcinoma of, scintigram of, 199
diagnostic imaging of, 198–200
Thyrotoxicosis, as paraneoplastic syndrome, perioperative management of, 56–57
Tibia, open fracture of, in gunshot injuries, 1120
Tiletamine-zolazepam, for crash-type anesthesia induction, in trauma patient, 1080
Tissue damage, with gunshot injuries, 1114–1116
Tissue flaps, in surgical oncology, 103
Tissue grafts, in surgical oncology, 104
Tissue seeding, in surgical oncology, 102–103
Toggle-pin fixation, for coxofemoral joint reduction, 1184–1185
Tongue, in cats, collagenolytic granuloma of, 931–932
Topical shampoo, for feline dermatophytosis, 911–913
Torso, lymphocenters of, 156
Toxic epidermal necrolysis, in cats, differential diagnosis of, 877
Toxoplasmosis, in cats, cutaneous manifestations of, 949–950
Trachea, endoscopy of, oncologic applications of, 175
Tracheostomy, in mandibular fracture, 1128–1129
Tranquilizers, for feline psychogenic alopecia, 861
Transaminases, in liver disease, 258
Transarticular pinning, for coxofemoral joint reduction, 1185
Transdermal analgesia, for pain, in surgical oncology patient, 88
Transforming growth factor beta, for impaired wound healing, 118–119
Transfusion medicine, canine blood groups in, 1323–1332
Transfusion reaction(s), canine, acute hypersensitivity, 1344–1346
categorization of, 1335
clinical significance of, 1334
diagnosis and treatment of, 1358
general considerations in, 1335
hemolytic, acute, 1336–1342
acute renal failure as, 1340
components contributing to, 1338
development of shock as, 1339–1340
pathophysiology of, 1336–1339
recognition of, 1340–1342
treatment of, 1341–1342
delayed, 1342
prevention of, 1343–1344
historic overview of, 1333–1334
immune-mediated, 1336
delayed, 1348–1350
immunosuppression in, 1349–1350
neonatal isoerythrolysis, 1349
post-transfusion purpura, 1348
nonhemolytic, 1344–1350
management of, 1333–1363
non-immune-mediated, 1350–1354
acidosis, 1356
acute, 1350, 1355–1356
air embolism, 1355
bacterial contamination, 1352–1353
circulatory overload, 1351–1352
citrate toxicity, 1353
cogulopathy, 1355
contaminated blood, 1350
delayed, 1356–1357
disease transmission, 1356–1357
hemolysis, 1350
hemosiderosis, 1357
hyperammonemia, 1355
hypothermia, 1355
mechanical hemolysis, 1350
pulmonary microembolism, 1355–1356
thermal hemolysis, 1351
with blood component therapy, in cancer patients, 1411–1412
Transfusion therapy, in emergency and critical care medicine, 1365–1385. See also Blood transfusion(s).
Trauma, and joint luxations, 1175–1196.
See also Joint(s).
thoracic, fracture-associated, management of, 1031–1046. See also Thoracic trauma.
Trauma patient, anesthesia of, 1073–1092
analgesia, 1081–1084
induction, 1079–1081
premedication, 1077–1079
problems and protocols, 1084–1090
antibiotic therapy for, 1023–1024
diagnostic testing in, 1018–1019
fluid therapy in, 1019–1023
general nursing care in, 1024–1025
management of, 1015–1029
physical examination, 1015–1018
physical therapy in, 1025–1028
Tretinoin, for feline dermatoses, 997
Tricyclic antidepressants, for chronic pain,
in surgical oncology patient, 91–92
for feline dermatoses, 991
for feline psychogenic alopecia, 861
Trientine, for copper-associated hepatopathies,
Trombiculiasis, in cats, and excess hair loss, 857
Tru-Cut biopsy needle, 279–280
Tube alimentation, in mandibular fracture,
Tularemia, cutaneous manifestations of,
Tumor(s), effect on nutritional status,
fine-needle biopsy of, 35
heterogeneity of, 231
circumvention of, 238
metastases of, 229–245
cascade of, 231–233
circumvention of, 238
control vs eradication of, 237–239
microscopic, implications of, 235
pattern and organ preference in, 234–235
treatment of, obstacles to success in, 236
timing of, 236–237
progression of, 230–231
prometastatic phenotypes in, expression of, 233–234
Tumor-related factors, and wound healing, 113
Tumor volume, increase in, and chemotherapy failure, 136
and radiation therapy failure, 141
Ulcer(s), in cats, diagnostic procedures utilizing, 871–873
Ulcerative dermatosis, in cats, differential diagnosis of, 880–881
Ulcerative lesions, oral, in cats, cytology of, 872
Ulcerative skin disease, in cats, 871–885
causes of, 874
differential diagnosis of, 873–883
Ulcerative stomatitis, in cats, causes of, 874
Ultrasound, for cats, 806
Ultrasoundography, abdominal, for acute liver failure, 445–446
as diagnostic imaging modality, 184–185
hepatic imaging with, 317–327
in liver biopsy, 281–285
in liver neoplasia, 425
in portal hypertension, 472
Urea cycle, of cat, 369
Urinalysis, in acute liver failure, 444–445
in feline idiopathic hepatic lipidosis, 360
Urinary tract, examination of, in trauma, 1018–1019
infections of, with long-term diabetes mellitus, 744–745
surgery of, in oncology patient, infection with, 83
Urine glucose, monitoring of, 580–581
Urogenital oncologic emergency, 213–215
clinical presentation and diagnosis of, 214
pathophysiology of, 213
surgical therapy and aftercare of, 214–215
Urogenital tract, diagnostic imaging of, 196
Ursodeoxycholate, for long-term liver disease, 510
for primary biliary cirrhosis, 510
for primary sclerosing cholangitis, 510–511
mechanism of action of, 511–513
toxicity of, 509
Ursodeoxycholic acid, for cholestatic long-term hepatitis, 511
for feline idiopathic hepatic lipidosis, 366
for gallstones, 378
Urticaria, with feline blood transfusion, 1320
Uveitis, with canine diabetic cataracts, 668
Vaccines, in cats, fibrosarcoma associated with, 968–969
Vacuole formation, in canine diabetic cataracts, 667
Vascular changes, and diabetic neuropathy, 726
Vascular dysfunction, transfusion for, 1393–1394
Vascular resistance, increased, and portal hypertension, 464–465
Vasoconstrictors, for portal hypertension, 474
Vasodilators, for portal hypertension, 474
Venousous bites, in cats, differential diagnosis of, 879
Vaccines, in cats, fibrosarcoma associated with, 968–969
Vacuole formation, in canine diabetic cataracts, 667
Vascular changes, and diabetic neuropathy, 726
Vascular dysfunction, transfusion for, 1393–1394
Vascular resistance, increased, and portal hypertension, 464–465
Vasoconstrictors, for portal hypertension, 474
Vasodilators, for portal hypertension, 474
Venousous bites, in cats, differential diagnosis of, 879

Urine glucose, monitoring of, 580–581
Urogenital oncologic emergency, 213–215
clinical presentation and diagnosis of, 214
pathophysiology of, 213
surgical therapy and aftercare of, 214–215
Urogenital tract, diagnostic imaging of, 196
Ursodeoxycholate, for long-term liver disease, 510
for primary biliary cirrhosis, 510
for primary sclerosing cholangitis, 510–511
mechanism of action of, 511–513
toxicity of, 509
Ursodeoxycholic acid, for cholestatic long-term hepatitis, 511
for feline idiopathic hepatic lipidosis, 366
for gallstones, 378
Urticaria, with feline blood transfusion, 1320
Uveitis, with canine diabetic cataracts, 668

Vaccines, in cats, fibrosarcoma associated with, 968–969
Vacuole formation, in canine diabetic cataracts, 667
Vascular changes, and diabetic neuropathy, 726
Vascular dysfunction, transfusion for, 1393–1394
Vascular resistance, increased, and portal hypertension, 464–465
Vasoconstrictors, for portal hypertension, 474
Vasodilators, for portal hypertension, 474
Venousous bites, in cats, differential diagnosis of, 879

Vaccines, in cats, fibrosarcoma associated with, 968–969
Vacuole formation, in canine diabetic cataracts, 667
Vascular changes, and diabetic neuropathy, 726
Vascular dysfunction, transfusion for, 1393–1394
Vascular resistance, increased, and portal hypertension, 464–465
Vasoconstrictors, for portal hypertension, 474
Vasodilators, for portal hypertension, 474
Venousous bites, in cats, differential diagnosis of, 879
Vertebral body plating, for spinal fracture/luxation stabilization, 1166
Vernacular medicine, imaging modalities used in, 184
Villous atrophy, with diabetes mellitus, 733
Vinca alkaloids, effects on wound healing, 115–116
Viral diseases, in cats, cutaneous, 945–948
differential diagnosis of, 880
Viral infections, and acute liver failure, 440
Vitamin(s), in hepatic encephalopathy, 350
Vitamin E, for copper-associated hepatopathies, 410
Vitamin K, for hemorrhage, in acute liver failure, 454
metabolism of, in liver disease, 490
Vitamin K-responsive coagulopathy, transfusion for, 1397
Volume replacement, in resuscitation from hemorrhage, critical need for red blood cells in, 1369–1370
Vomiting, in feline idiopathic hepatic lipidosis, 365
with feline blood transfusion, 1317
von Willebrand’s disease, prevalence by breed, 277
transfusion for, 1391–1392

Waterless hand cleaner, for feline grooming, 773
West Highland white terrier, chronic active hepatitis in, 391–392
copper-associated hepatopathy in, 412–413
Whole blood, characteristics of, 1278
Wilson’s disease, copper metabolism in, 402
Wood’s lamp examination, for feline dermatophytosis, 908–909
in feline dermatology, 785–786
Wound(s), cleansing of, in open fracture management, 1100–1101

in penetrating joint injury, 1209–1211
closure of, with penetrating joint injury, 1212–1213
in surgical oncology, environment of, 76
lavage of, 103
protection of, 102–103
reconstruction of, 103–104
infection of, in open fracture management, 1105–1106
initial care of, in open fracture management, 1098
Wound healing, impaired, 109–129
basic fibroblast growth factor for, 122
chemotherapy and, 114–117
clinical perspective on, 122–124
epidermal growth factor for, 119–121
pharmacologic modulation of, 118–122
platelet-derived growth factor for, 121–122
transforming growth factor beta for, 118–119
in cancer catabolism, 65
models to study, 111
multifactorial nature of, 111–113
concurrent systemic diseases, 113
nutritional status, 113
radiation therapy, 111–113
tumor-related factors, 113
physiology of, 109–110

Xenodine, for feline dermatoses, 1000
Xerostomia, with long-term diabetes mellitus, 732

Yeast, scraping/impression smears for, in feline dermatology, 784–785

Zinc, for copper-associated hepatopathies, 406–408
<table>
<thead>
<tr>
<th>Publication Title</th>
<th>1.</th>
<th>2.</th>
<th>3.</th>
<th>4.</th>
<th>5.</th>
<th>6.</th>
<th>7.</th>
<th>8.</th>
<th>9.</th>
<th>10.</th>
<th>11.</th>
<th>12.</th>
<th>13.</th>
<th>14.</th>
<th>15.</th>
<th>16.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Veterinary Clinics of North America: Small Animal Practice</td>
<td>0</td>
<td>1</td>
<td>9</td>
<td>5</td>
<td>6</td>
<td>1</td>
<td>6</td>
<td>7/28/95</td>
<td>6</td>
<td>6</td>
<td>593.00</td>
<td>9,240</td>
<td>9,300</td>
<td>5,758</td>
<td>6,301</td>
<td>6,578</td>
</tr>
<tr>
<td>Jan/Mar/May/Jul/Sep/Nov (Bi-monthly)</td>
<td>Jan/Mar/May/Jul/Sep/Nov (Bi-monthly)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Full Names and Complete Mailing Addresses of Publisher, Editor, and Managing Editor (Do Not Leave Blank)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Theresa Monturano, W. B. Saunders Company, The Curtis Center, Independence Square West, Phila., PA 19106-3399</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carol Wolfe, W. B. Saunders Company, The Curtis Center, Independence Square West, Phila., PA 19106-3399</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Managing Editor (Name and Complete Mailing Address)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>W. B. Saunders Company, Harcourt Brace &amp; Company, 6277 Sea Harbor Drive, Orlando, FL 32887-4800, Orange County</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

11. Known Bondholders, Mortgagees, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Bonds, Mortgages, or Other Securities. If none, check here. None

12. For completion by nonprofit organizations authorized to mail in special rates, the purpose, function, and nonprofit status of this organization and the exempt status for federal income tax purposes. (Check one) Has Not Changed During Preceding 12 Months Has Changed During Preceding 12 Months (If changed, publisher must submit explanation of change with this statement)

PS Form 3526, October 1994

(See Instructions on Reverse)